Inhibitory effect of selected herbal supplements on CYP450-mediated metabolism : an in vitro approach by White, Charlize
INHIBITORY EFFECT OF SELECTED HERBAL SUPPLEMENTS ON 
CYP450 - MEDIATED METABOLISM - AN IN VITRO APPROACH. 
by 
CHARLIZE WHITE 
Thesis presented in partial fulfilment of the requirements for the degree 
Master of Science (Pharmacology) 
Division of Clinical Pharmacology 
Department of Medicine and Health Sciences 
University of Stellenbosch 
Supervisor: Bernd Rosenkranz 
Professor and Head, Division of Pharmacology, Faculty of Medicine and Health Sciences 
Co-supervisor: Patrick Bouic 
Professor, Division of Medical Microbiology, Faculty of Medicine and Health Sciences 
March 2016
i 
 
 
DECLARATION 
 
By submitting this thesis, I declare that the entirety of the work contained therein is my own, original 
work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that 
reproduction and publication thereof by Stellenbosch University will not infringe any third party 
rights and that I have not previously in its entirety or in part submitted it for obtaining any 
qualification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2016 University of Stellenbosch 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za
ii 
 
ABSTRACT 
INTRODUCTION 
Herbal products are popularly used as complementary and alternative medicines to treat a variety of 
conditions. Often patients use them in conjunction with conventional medicines. Herbal products 
contain many pharmacologically active phytochemicals that may interfere with the absorption, 
distribution, metabolism, and elimination of medicines. This interaction can lead to an increase of 
the plasma concentrations of other medicines to toxic levels, or to their decrease below therapeutic 
levels, resulting in lack of efficacy. The liver cytochrome P450 (CYP) enzymes are responsible for the 
metabolism of a large majority of medicines. In order to provide more information on the potential 
interaction between African herbal medicines and conventional medicines, the present study has 
investigated the inhibition of selected CYP enzymes by three popular South African medicinal plants, 
Buchu, African ginger, and Warburgia salutaris.  
METHODS 
Buchu capsules, African ginger, and Warburgia salutaris tablets were obtained in a local pharmacy. 
60% methanol/water extracts were prepared and analysed by GC-MS to reveal the composition of 
the volatile components of each product. Fluorogenic inhibition assays were conducted using Vivid® 
recombinant CYP screening kits according to the manufacturer’s protocol. This protocol included the 
pre-incubation of herbal extracts, recombinant CYP isoform and cofactor solution. The metabolic 
reaction was initiated by the addition of CYP-specific substrate and NADP+; the solution was 
incubated for 30 minutes at 37°C, after which fluorescence was measured using a microplate reader. 
The percentage remaining activity was calculated and used to determine the IC50 values of each 
herbal product. Time - dependent inhibition (TDI) was evaluated using the normalized ratio, NADP+-, 
concentration -, and time - dependent approaches.  
RESULTS 
The GC-MS analysis revealed monoterpenes, sesquiterpenes, and alkane hydrocarbons in the 
volatile component. Warburgia salutaris, African ginger, and Buchu inhibited CYP2C19 with IC50 
values of 5.88 μg/ml, 32.38 μg/ml, and 53.52 μg/ml, respectively.  Likewise, the IC50 values of 5.64 
μg/ml, 1.09 μg/ml, and > 100 μg/ml were obtained for inhibition of CYP3A4 by Warburgia salutaris, 
African ginger, and Buchu, respectively. Using the normalized ratio, Warburgia salutaris and African 
ginger showed time- and concentration - dependent inhibition of CYP1A2, and Buchu showed 
intermediate TDI effects that were not concentration dependent. All three extracts showed TDI of 
CYP3A4; the inhibition displayed by Buchu and Warburgia salutaris was NADP+ dependent. African 
ginger was the only extract to show NADP+ dependent inhibition of CYP1A2.  A kinetic TDI assay 
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showed that the IC50 value of African ginger decreased over time, indicating TDI. Warburgia salutaris 
was not a time-dependent inhibitor of CYP3A4, and Buchu may have a limited time-dependent 
inhibitory effect.  
CONCLUSION 
Warburgia salutaris, African ginger, and Buchu have the potential to cause clinically relevant herb-
drug interaction, if sufficient concentrations are achieved in vivo. Further studies are needed to 
confirm this finding.    
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ABSTRAKT 
INLEIDING 
Kruie produkte word gebruik as komplementêre en alternatiewe medisynes om ‘n verskeidenheid 
van gesondheidstoestande te behandel. Pasiënte gebruik dit dikwels tesame met konvensionele 
medisynes.  Kruie produkte bevat verskeie farmakologiese aktiewe plant chemikalieë wat met die 
absorpsie, distribusie, metabolisme en eliminasie van medisyne inmeng. Hierdie interaksie kan 
aanleiding gee tot ‘n toename in plasma konsentrasies van die ander medisynes tot toksiese vlakke 
of tot hul afname na onder terapeutiese vlakke wat dan aanleiding gee tot ‘n gebrek aan 
doeltreffendheid. Die lewer sitochroom P450 (CYP) ensiemes is verantwoordelik vir die metabolisme 
van die meeste medisynes.  Die huidige studie is onderneem in ‘n poging om meer inligting 
aangaande die potensiële interaksies tussen Afrika kruie medisynes en konvensionele medisynes te 
bepaal.  Die inhibisie van geselekteerde CYP ensiemes deur drie gewilde Suid Afrikaanse medisinale 
plante, Buchu, Afrika gemmer en Warburgia salutaris is ondersoek. 
 
METODES 
Buchu kapsules, Afrika gemmer, en Warburgia salutaris tablette is by ‘n plaaslike apteek bekom.  
60% methanol/water ekstrakte is voorberei en die samestelling van die vlugtige komponete van elke 
produk is deur die analises met GC-MS bepaal. Fluoroserende inhibisie bepalings is uitgevoer deur 
gebruik te maak van Vivid® rekombinante CPY siftings toetse.  Hierdie protokol sluit in die pre-
inkubasie van die kruie ekstrakte, rekombinate CYP isoform en ko-faktor oplossing.  Die metaboliese 
reaksie word geaktiveer deur die byvoeging van CYP-spesifieke substrate en NADP+; die oplossing is 
vir 30 minute by 37oC geinkubeer, waarna fluorosensie deur middel van ‘n mikroplaatleser gemeet 
is. Die persentasie oorblywende aktiwiteit is bereken en daarna gebruik om die IC50 waardes van elke 
kruie produk te bepaal.  Die tydafhanklike inhiberende uitwerking (TAI) is bereken deur gebruik te 
maak van die genormaliseerde verhouding, NADP+-, konsentrasie-, en tyd afhanklike benaderings. 
 
RESULTATE 
Die GC-MS analises het monoterpiene, sekwiterpiene, en alkaan koolwaterstowwe aangetoon.  
Warbugia salutaris, Afrika gemmer, en Buchu het CYP2C19 geinhibeer met IC50 waardes van 5.88 
ug/ml, 32.38 ug/ml, en 53.52 ug/ml onderskeidelik.  Eweneens is IC50 waardes van 5.64 ug/ml, 1.09 
ug/ml en > 100 ug/ml onderskeidelik verkry met inhibisie van CYP3A4 deur Warburgia salutaris, 
Afrika gemmer en Buchu.  Deur gebruik te maak van die genormaliseerde verhouding wys Warburgia 
salutaris en Afrika gemmer tyd en konsentrasie-afhanklike inhibisie van CYP1A2. Buchu wys 
intermediêre TDI effekte wat nie konsentrasie afhanklik is nie.  Al drie ekstrakte het ‘n TDI van 
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CYP3A4 aangedui; die inhibisie aangetoon deur Buchu en Warburgia salutaris was NADP+ afhanklik.  
Afrika gemmer was die enigste ekstrak wat NADP+ afhanklike inhibisie van CYP1A2 aangetoon het.  ‘n 
Kinetiese TDI toets het gewys dat die IC50 waarde van Afrika gemmer oor tyd afneem wat TDI aandui. 
Warburgia salutaris is nie ‘n tyd-afhanklike inhibitor van CYP3A4 nie en Buchu kan dalk ‘n beperkte 
tyd-afhanklike inhibitoriese effek hê. 
 
GEVOLGTREKKING 
Warburgia salutaris, Afrika gemmer en Buchu het die potensiaal om klinies relevante kruie-medisyne 
interaksies te veroorsaak indien genoegsame konsentrasies in vivo bereik word. Verdere studies is 
nodig om hierdie bevindinge te bevestig. 
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CHAPTER ONE 
INTRODUCTION TO STUDY 
 
1.1 Traditional medicine 
Medicinal plants have long been used for the maintenance of health and the treatment of diseases. 
South Africa’s rich biodiversity includes many indigenous and endemic plant species, some of which 
may possess various health benefits. The knowledge of these health benefits forms an integral part 
of traditional African medicine, a holistic practice developed over generations before the advent of 
modern medicine. 
Traditional African medicine combines herbalism and spirituality, and its health practitioners are 
represented by three types of healers, the herbalist (inyanga), the diviner (isangoma), and the faith 
healer (umthandazi) (Kale, 1995). Even in the era of modern medicine, traditional medicine has 
remained a viable alternative of health care treatment as it is easily accessible (especially in rural 
areas), relatively affordable, and is culturally accepted (Babb et al., 2007).  
With the HIV/AIDS and tuberculosis pandemic facing the country, the accessibility of traditional 
medicine in relation to modern health care has resulted in a dual health care system. Indeed, the 
South African government has promoted the integration of traditional healers into its legislative 
framework (Gqaleni et al., 2007). Various medicinal plants, such as Lesseria frutescens, have been 
claimed to possess therapeutic and even anti-HIV effects (Harnett et al., 2005) and most medicinal 
plants are used as immune boosters or in the management of symptoms. Nonetheless, the increased 
interest in the potential of African herbal medicine has led to the commercialization of many 
indigenous plant species.  
In some parts of the world, these commercialized herbal products are sold as “phytomedicines” and 
are subject to the same regulatory standard as regular medicine (Zhang, 1998). In South Africa, these 
products are sold as complementary medicines and like other medicines, are regulated by the 
Medicines Control Council (MCC) of South Africa. Under new legislation, certain products that 
contained banned or scheduled substances were withdrawn from the market. Therefore, products 
such as milk thistle, which contains silymarin, require a prescription from a general practitioner and 
products such as Piper methysticum, which is reported to cause liver damage (Ernst, 2007), is no 
longer available in South Africa. In addition, complementary medicines have to be labelled correctly 
and all products are to be reviewed by the MCC over the course of a few years (PSSA, 2014).  Despite 
regulation, these complementary medicines are still not subject to the same safety and efficacy trials 
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required of prescription medications. Therefore the product information contains little information 
on safety issues, including warnings, contra-indications, or considerations regarding the concomitant 
usage of these complementary medicines with conventional medicines. 
Complementary and alternative medicines (CAM) are defined as practices or medical products that 
are chosen as adjuncts or alternatives to Western medical approaches (Debas et al., 2006). 
“Complementary” medicines refer to practices and products together with conventional medicines, 
while “alternative” medicines refer to approaches in place of conventional medicines. CAMs include 
natural products such as herbs, vitamins, minerals, and probiotics. These are usually regulated and 
sold as dietary supplements. Other CAMs include acupuncture, traditional medicine, naturopathy, 
massage therapy, meditation, and hypnotherapy. 
 
1.2 Herb - drug interactions 
The increase in the popularity of herbal products has prompted the investigation into the potential 
interaction between herbs and prescription medication (Fugh-Berman & Ernst, 2001).   Most herbal 
products, as well as orthodox drugs, are metabolized by phase I metabolic enzymes, the liver 
cytochrome P450 enzymes (CYP450), and phase II metabolic enzymes, uridine 
diphosphoglucuronosyl transferase (UGT), N-acetyl transferase (NAT), glutathione S-transferase 
(GST) and sulfotransferase (ST) (Zhou et al., 2003).  As these enzymes possess a great deal of 
variation (Denisov et al., 2005) and are able to metabolize a large variety of biomolecules, the 
overlapping substrate specificity also allows modulation of enzyme activity. Consequently, the 
binding of one substrate to the enzyme active site can influence the metabolism of another 
substrate.  
This is also true for drug transporters such as P- glycoprotein (P-gp) that play a significant role in the 
absorption, distribution, and elimination of drugs. Interaction by herbal products at any stage of 
metabolism can therefore alter the pharmacokinetic profile of drug action. 
Drug interactions have various outcomes. The interaction may result in enzyme induction, where the 
metabolism of one compound (drug, herbs, pollutants) may result in an increased biotransformation 
of another drug. As a result, the drug may exhibit decreased efficacy as it is metabolized too rapidly 
to produce the desired effect.  Alternatively, induction may result in toxicity if the drug action 
requires active metabolites, since an increased metabolism of a drug would increase the amount of 
drug metabolite (Ogu & Maxa, 2000). Drug interactions may also result in inhibition, where 
metabolism of a drug is decreased. This may lead to elevated levels of the active drug – a potential 
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for drug toxicity – or it may lead to decreased efficacy if the drug requires biotransformation (Ogu & 
Maxa, 2000).  
Unlike conventional medicines, herbal products contain many phytochemicals. As many of these 
phytochemicals are pharmacologically active compounds such as alkaloids, steroids, terpenoids, 
flavonoids and coumarins, ingestion of these products with conventional medicines increases the 
likelihood of herb-drug interactions (HDI) (Izzo, 2005). These phytochemicals have been shown to 
have biological significance and possess the potential to affect pathological states (Han et al., 2007). 
In addition, most individuals assume the safety of natural products, which may be the reasoning 
behind an individual’s polypharmacy. Therefore, there is a high risk of interactions between herbal 
products and prescription medicines. Adequate scientific knowledge of potential HDI is needed to 
aid in advising health care professionals in co-administration of herbal products to decrease the risk 
of toxicity or inefficacy of drug treatments. This is especially relevant for complex treatment 
regimens, such as highly active anti-retroviral treatment, anti-tubercular treatment, and 
chemotherapy.    
 
1.2.1 Herb - drug interactions of African herbal medicine 
In Africa, usage of herbal medicine in combination with Westernized medicine is a common, yet 
unadvised, practice that may have serious implications. Unlike the more popular herbal medicines 
used in developed countries, very little data on the potential of African herbal medicines to cause 
HDI exist. Therefore, there is a great need for further research in this specific field of HDI for these 
products. The current information on the HDI of African herbal medicines from both in vitro and in 
vivo studies is summarized below.    
 
1.2.1.1 Lessertia frutescens  
Lessertia frutescens, commonly known as Cancer bush, is traditionally used in the treatment of fever, 
diabetes, colds, influenza, cough, chest complaints, asthma, stress and anxiety, rheumatism, muscle-
wasting, open wounds, gastric and intestinal complaints, dysentery, liver and kidney conditions, 
urinary tract infections, and cancer (Watt & Breyer-Brandwijk 1962). In addition, it is also used as an 
immune booster by HIV/AIDS patients (Prevoo et al., 2004), and the South African Ministry of Health 
has even recommended its usage as a herbal treatment of HIV/AIDS (SADC, 2002).  
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However, in vitro studies have shown the potential of L. frutescens to cause HDI. L. frutescens 
demonstrates near complete inhibition (96%) of CYP3A4 and dose-dependent activation of the 
pregnane X receptor (PXR) (Mills et al., 2005). A study conducted by Fasinu (2013) using human liver 
microsomes showed that not only does L. frutescens inhibit CYP3A4, but also that the inhibition 
increases with increased consumption of the herb. In addition, a study by Minocha et al. (2011) to 
determine the effects of a single dose and long-term administration of L. frutescens on nevirapine 
bioavailability in rats showed that although there was no significant difference in the oral 
bioavailability of nevirapine before and after the single dose administration, there was a 50% 
decrease in bioavailability parameters (AUC, Cmax) after five days of treatment. In the same study, a 
two - threefold increase in CYP3A4 mRNA expression was observed in the small intestine and liver 
tissue, indicating that the decreased bioavailability of nevirapine may be due to the increased 
metabolism by CYP3A4. If this HDI were to occur in humans, sub-therapeutic levels of nevirapine 
may be achieved, which could result in treatment failure and drug resistance.  
 
1.2.1.2 Hypoxis hemerocallidea 
H. hemerocallidea, also known as the African potato, is used in the treatment of muscle-wasting 
diseases, cancer, tuberculosis, benign prostatic hypertrophy, urinary tract infections, cardiac 
diseases, impotency, intestinal parasites, cancer, headaches, burns, ulcers, colds, influenza, 
hypertension, diabetes, psoriasis, inflammation, and diabetes (Watt & Breyer-Brandwijk, 1962; Mills 
et al., 2005).  Like L. frutescens, H. hemerocallidea is also used as an immune booster in the 
management of HIV/AIDS and recommended by the South African Ministry of Health (SADC, 2002).  
The main phytochemical constituent in African potato is hypoxoside, which is converted in the 
gastrointestinal tract to rooperol through bacterial β -glucosidase activity (Nair et al., 2007). Assays 
employing the pure compounds of hypoxoside and rooperol showed that hypoxoside did not show 
any in vitro CYP inhibition but rooperol displayed potent inhibition (Laporta et al., 2007; Nair et al., 
2007). In addition, hypoxoside was a potent inducer of P-glycoprotein, while rooperol did not have a 
significant effect (Nair et al., 2007). 
Aqueous and ethanolic extracts of H. hemerocallidea have shown to have an inhibitory effect of 
CYP3A4 activity and to activate PXR in a dose-dependent manner (Mills et al., 2005).  Studies done 
with Caco-2 intestinal cells showed that extracts prepared according to ethnomedicinal guidelines 
decrease efflux of nevirapine, indicating a possible increased bioavailability (Brown et al., 2008). 
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1.2.1.3 Other medicinal herbs 
Harpagophytum procumbens, also known as devil’s claw, is used to treat arthritis, rheumatism, sore 
joints, diabetes, gastrointestinal problems, neuralgia, headache, gout, and loss of appetite (van Wyk, 
1997).  In vitro studies have shown that H. procumbens increases the expression of P-gp transporters 
and inhibits P-gp efflux of calcein AM from human kidney-2 (HK-2) proximal tubule cells (Nair et al., 
2007). H. procumbens also shows weak inhibitory action on CYP1A2 and CYP2D6, and moderate 
inhibitory activity on CYP2C8, CYP2C9, CYP2C19, and CYP3A4 (Ungar et al., 2004). 
Echinacea purpurea, commonly known as Echinacea, is used in the treatment of respiratory 
infections, colds, and influenza.  Although not indigenous to sub-Saharan Africa, the popularity of 
Echinacea is increasing due to its immunomodulatory and antiviral properties. In vitro data suggests 
that Echinacea is a reversible inhibitor of CYP1A2, CYP2C19, and CYP3A4, and upregulates the 
expression of CYP1A2, CYP3A4, and multidrug-resistant protein 1/P-glycoprotein (MDR1) genes 
(Awortwe, 2015).  In vivo studies indicate that Echinacea reduces the oral clearance of CYP1A2 
substrates and selectively modulates both hepatic and intestinal CYP3A activity (Gorski et al., 2004). 
An in vitro study using human liver microsomes (Fasinu, 2013) screened 15 South African medicinal 
plants for CYP450 inhibitory activity. Of the 15 plants that were screened, 12 showed varying 
degrees of CYP1A2 inhibition with Spirostachys africana exhibiting the most potent inhibition. Eight 
of the 15 plants showed potent inhibition of CYP2C9, and seven plants, Acacia karroo, Capparis 
sepiaria, Chenopodium album, Pachycarpus concolor, Ranunculus multifidus, Lessertia frutescens, 
and Zantedeschia aethiopica, inhibited CYP2C19 to varying degrees. Of the 15 plants, only two herbs, 
Alepidea amatymbica and Tulbaghia violacea, did not possess CYP3A4 inhibitory activity. As these 
plants are commonly employed in the treatment of conditions such as respiratory problems, 
gastrointestinal problems, skin problems, bacterial and viral infections, urinary tract infection, 
diabetes, cancer, and venereal diseases, they often are used concomitantly with conventional 
medicines (Fasinu, 2013).  
 
1.3 Inhibition of CYP enzymes 
HDI and drug-drug interactions (DDI) are often the result of inhibition, activation, or induction of the 
phase I and II metabolic enzymes and the various drug transporters. This study focuses on herb-drug 
interactions as a result of CYP450 inhibition, and the following review focuses on the various 
mechanisms of inhibition.  
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The mechanisms of CYP inhibition can be broadly classified into reversible and irreversible inhibition 
(time - dependent inhibition). Reversible inhibition can be further classified into competitive, non-
competitive, uncompetitive, and mixed inhibition (Berg, 2002). Irreversible (time - dependent) 
inhibition includes the subset of mechanism - based inhibition, which can be further classified into 
quasi - reversible inhibition and true irreversible inhibition.  
 
1.3.1 Competitive inhibition 
In competitive inhibition, a molecule (inhibitor) similar to the substrate competes with a substrate 
for the active site of the enzyme. The molecule binds to the enzyme in a reversible manner and 
inhibits the binding of the substrate. As the overall structure of the enzyme is not affected by the 
inhibitor, the enzyme is still able to catalyse any substrate that does bind to the active site. In 
addition, competitive inhibition can be overcome by raising the concentration of the available 
substrate.  The metabolic rate of the reaction (v) can be expressed as:  
 
v = Vmax [S]/ Km(1+[I]/Ki)  +  [S]   Equation 1.1 
 
Where Vmax is the maximum velocity of the reaction, [S] is the substrate concentration, Km is the 
Michaelis-Menten constant-the substrate concentration at which the reaction rate is half of Vmax, [I] 
is the inhibitor concentration, and Ki is the inhibition constant, which is the dissociation constant 
(Nelson & Cox, 2008).  
 
1.3.2 Non-competitive inhibition 
During non-competitive inhibition, the inhibitor does not bind to the active site, but rather binds to 
another site elsewhere on the enzyme. This binding affects the structure of the enzyme and 
therefore affects the ability of the substrate to bind to the active site. As a result, increasing the 
substrate concentration will not affect the degree of inhibition. The metabolic rate of the reaction 
can be expressed as:  
v = {Vmax/ (1+[I]/Ki)} [S]/Km + [S]   Equation 1.2 
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1.3.3 Uncompetitive inhibition 
In uncompetitive inhibition, the inhibitor only binds to the enzyme once the substrate has bound to 
the enzyme and cannot bind to the enzyme alone. Consequently, the likelihood of uncompetitive 
inhibition occurs at high concentrations of both substrate and enzyme. The metabolic rate of the 
reaction can be expressed as: 
v  = {V
max
/ (1+[I]/Ki)} [S]/Km/(1+[I]/Ki)  +  [S] Equation 1.3 
1.3.4 Mixed inhibition 
Mixed inhibition can be thought of as a “mixture” of competitive inhibition and uncompetitive 
inhibition. The inhibitor can bind to the enzyme before the substrate binds (such as in competitive 
inhibition), or can bind to the enzyme substrate complex, after the enzyme has bound (such as in 
uncompetitive inhibition). However, the inhibitor has a greater affinity for one of the two states.  
The metabolic rate of the reaction can be expressed as: 
 
v  = Vmax/ (1+[I]/Ki) + (1 + Ks/[S]) × (1 + [I]/Ki)  Equation 1.4 
 
1.3.5 Time - dependent inhibition 
Time - dependent inhibition is a process whereby the inhibitor increases in potency upon prolonged 
exposure to the enzyme during the pre-incubation period. Potential mechanisms of this process 
include the formation of metabolites that possess stronger inhibitory activity than the parent 
molecule and mechanism-based inhibition (MBI) - the inactivation of an enzyme through the 
formation of metabolites that bind irreversibly to the enzyme. In this case, de novo synthesis of the 
enzyme is required to maintain the original level of enzyme activity. 
MBI can further be classified into quasi-irreversible and true irreversible inhibition.  In quasi-
irreversible inhibition, the metabolite formed coordinates with the ferrous form of the CYP heme, 
forming a metabolic intermediate complex (MIC) that renders the enzyme catalytically inactive. In 
true irreversible inhibition, the substrate covalently binds to the enzyme. 
 
1.4 Cytochrome P450 enzymes 
Cytochrome P450s (CYP450) are a superfamily of monooxygenases responsible for the phase I 
oxidation of more than 95% of all drugs available on the market (Alden et al., 2010). They are also 
Stellenbosch University  https://scholar.sun.ac.za
8 
 
responsible for the biosynthesis of steroid hormones, cholesterol, prostaglandins, bile acids, and 
thromboxane A2 (Nebert & Russell, 2002). These enzymes are located in the endoplasmic reticulum 
of organs such as the liver, kidneys, skin, intestines, placenta, brain and lungs (Flockhart, 2007), but 
the majority of CYP450 - mediated metabolism occurs in the liver, the primary site for xenobiotic 
biotransformation (Ogu & Maxa, 2000).    
The majority of drugs are metabolized at clinically relevant concentrations by one or a few 
isoenzymes (Zanger & Schwab, 2013). A single isoenzyme is therefore responsible for the oxidation 
of many different drugs, as CYP450s possess enough structural diversity to allow the binding of 
various substrates (Denisov et al., 2005). As a result, 90% of all xenobiotics are metabolized by six 
isoenzymes, namely, CYP1A2, CYP2C9, 2C19, 2D6, and 3A4/5 (Wilkinson, 2005). 
 
1.4.1 Cytochrome P450 1A2 
Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1 family of heme proteins, also consisting of 
CYP1A1 and CYP1B1. Expression of both CYPs 1A1 and 1B1 in humans is low and occurs mainly in 
extra-hepatic tissue. In addition, both enzymes contribute little to drug metabolism and clearance of 
xenobiotics, however, CYP1A1 does have a significant role in the activation of procarcinogens 
(Shimada et al., 1992). CYP1A2 is the primary CYP1 enzyme and accounts for 13-15% of total CYP450 
content (Sridhar et al., 2012). It is predominantly expressed in the liver and is responsible for the 
phase I metabolism of drugs such as propranolol, tacrine, theophylline, clozapine, and verapamil 
(Flockhart, 2007). 
CYP1A2 plays a significant role in the metabolism of endogenous substances (Guengerich, 1993) and 
environmental toxins. It is also responsible for the activation of many environmental carcinogens, 
including certain mycotoxins, dietary heterocyclic amines, and the nitrosamines found in cigarette 
smoke (Faber et al., 2005). Consequently, its activity may affect an individual’s susceptibility to 
cancer (Sridhar et al, 2012; Faber et al., 2005) and higher enzyme activity, in some studies, has been 
associated with a higher prevalence of certain cancers (Lang et al., 1994; Horn et al., 1995). 
The most common probes for evaluation of CYP1A2 metabolism are phenacetin, caffeine, and 
melatonin. Caffeine is not often used as an in vitro probe, as its metabolism is extremely complex 
and difficult to monitor (Spaggiari et al., 2014). It is however, useful in in vivo phenotyping, as it is 
relatively safe and can be detected in non-invasive manner. It is also the probe recommended by 
regulatory authorities. Phenacetin O-deethylation is the most frequently employed marker reaction 
for in vitro metabolism, as it is highly specific at low substrate concentrations (Spaggiari et al., 2014).  
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Expression of CYP1A2 in the human liver is highly variable among individuals (Shweikl et al., 1993) 
and has shown to have a corresponding variability in enzyme activity and drug metabolism (Potkin et 
al., 1997). However, induction and inhibition of CYP1A2 has shown to be the most prominent factors 
influencing enzyme activity. CYP1A2 may be induced by cruciferous vegetables, chargrilled meat, 
polycyclic aromatic hydrocarbons, heavy exercise, smoking, caffeine intake (Faber et al., 2005), and 
by certain drugs such as carbamazepine, insulin, omeprazole, and rifampin (Flockhart, 2007). In 
addition, certain factors have shown to have an inhibitory effect of CYP1A2. These include drugs 
such as ciprofloxacin, fluvoxamine, furafylline, quinolone antibiotics, methoxsalen, and oral 
contraceptives (Flockhart, 2007; Gardner et al., 1983; Abernethy & Todd, 1985).  
 
1.4.2 Cytochrome P450 2D6 
Despite its relatively low abundance in the liver, cytochrome P450 2D6 (CYP2D6) is responsible for 
25% of all drug metabolism, and it metabolizes drugs from many different therapeutic classes. 
Substrates of CYP2D6 include opioid analgesics like codeine and tramadol, β-blockers like bufuralol 
and metoprolol, antidepressants like amitriptyline, paroxetine, and venlafaxine, anticancer drugs like 
tamoxifen, antipsychotics like aripiprazole and risperidone, and antiarrhythmics like propafenone, 
mexiletine, and flecainide (Ionnides, 2008; Stingl et al., 2012). 
Of all the CYP450 isoforms, CYP2D6 shows the most variation in the efficiency and abundance of 
enzyme expressed between individuals (Wang et al., 2009). This variation is largely due to genetic 
factors, but may also be a result of the broad substrate specificity of the enzyme. Genetic variation 
may result in increased or decreased protein expression, or even no protein or non-functional 
protein expression.  Individuals may possess non-functional or partially defective alleles that result in 
a phenotype known as “poor metabolizer,” which is present in about 7% of Caucasians, 2-7% of 
Africans, and less than 1% of Asians (Abraham & Adithan, 2001).  
The majority of the population exhibit the “extensive metabolizer” phenotype, while a small 
percentage of the population possesses various copies of the gene. These are known as “ultra-rapid 
metabolizers,” as they possess strong enzyme activity. Consequently, CYP2D6 activity ranges from 
complete deficiency to excessive metabolism (Wang et al., 2009; Bradford, 2002).  
The large variation in CYP2D6 substrates and inhibitors may also contribute to its variation in 
enzyme activity. The enzyme may be inhibited by drugs such as celecoxib, cocaine, ritonavir, 
ticlopidine, bupropion, paroxetine, and quinidine, whereas dexamethasone and rifampin are known 
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inducers of CYP2D6 (Flockhart, 2007).  Bufuralol 1’ - hydroxylation and dextromethorphan O-
demethylation are two commonly used marker reactions for enzyme activity. 
 
1.4.3 Cytochrome P450 2C9 
The cytochrome P450 2C subfamily is the second largest P450 subfamily after CYP3A4 and contains 
three active members, 2C8, 2C9, and 2C19. It accounts for approximately 18% of all hepatic CYP450s 
(Lee et al., 2002). Cytochrome P450 2C9 (CYP2C9) is the most prolifically expressed isoform of the 2C 
subfamily, responsible for the clearance of 15 - 20% of all drugs undergoing phase I metabolism 
(Sridhar et al., 2012; Lee et al., 2002). Substrates of CYP2C9 include the nonsteroidal anti-
inflammatory drugs celecoxib, diclofenac, ibuprofen, and naproxen, the alkylating anti-cancer 
prodrug cyclophosphamide, the sulfonylureas tolbutamide, glipizide, glimepiride, and the 
anticoagulant warfarin (Flockhart, 2007). 
Like CYP2D6, the gene encoding CYP2C9 enzymes is polymorphic, resulting in great variation of 
CYP2C9 activity between individuals (Lee et al., 2002). Poor metabolizers are therefore at greater 
risk of toxicity, especially as many CYP2C9 substrates have a narrow therapeutic index. CYP2C9 is 
inhibited by drugs such as fluconazole, amiodarone, fenofibrate, fluvastatin, fluvoxamine, isoniazid, 
lovastatin, sulfamethoxazole, and sulfaphenazole (Flockhart, 2007). Its enzyme activity may also be 
induced by rifampicin.  
The biotransformation of diclofenac to 4-hydroxydiclofenac and tolbutamide to 4-
hydroxytolbutamide are both suitable marker reactions for the evaluation of CYP2C9 activity 
(Spaggiari et al., 2014). 
 
1.4.4 Cytochrome P450 2C19 
Cytochrome P450 2C19 (CYP2C19) is a polymorphic enzyme that accounts for less than 5% of 
expressed CYP450 content in the liver, and 2 - 3% expressed CYP450 content in the small intestine 
(Paine et al., 2006). As with CYP2C9, it also belongs to the CYP2C family and is responsible for the 
primary metabolism of 10% of marketed drugs including, omeprazole, mephenytoin, and diazepam. 
Polymorphisms within the encoding genes of CYP2C19 result in variation of enzyme activity, leading 
to poor or enhanced metabolism of drugs.  
Inducers of CYP2C19 include rifampicin, prednisone, and artemisinin, and inhibitors include 
fluvoxamine, chloramphenicol, and ticlopidine (Foti & Wahlstrom, 2008).  CYP2C19 exclusively 
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metabolises (S) - mephenytoin to 4’-hydroxymephenytoin, which is therefore an ideal probe 
substrate for CYP2C19 enzyme activity (Spaggiari et al., 2014). 
 
1.4.5 Cytochrome P450 3A4 
Cytochrome P450 3A4 (CYP3A4) belongs to the CYP3A family, which also includes CYP3A5 and 
CYP3A7 isoforms (Guengerich, 1999). CYP3A4 is primarily expressed in the liver and the small 
intestine, accounting for approximately 40% of total hepatic cytochrome content and 50% of all CYP-
mediated drug metabolism (Guengerich, 1999). CYP3A4 expression is shown to be extremely 
variable within the population, displaying greater than 100 fold variation between individuals 
(Zanger & Schwab, 2013). 
Cytochromes belonging to the CYP3A subfamily have large active sites that bind to multiple 
structurally different substrates including antiarrhythmics such as quinidine, immune modulators 
such as cyclosporine A and tacrolimus, macrolide antibiotics such as clarithromycin and 
erythromycin, and benzodiazepines such as alprazolam, midazolam, triazolam, and diazepam 
(Shimada & Guengerich, 1989; Flockhart, 2007). In addition, other substrates include various 
antihistamines, anaesthetics, antifungals, analgesics, and endogenous substances like testosterone, 
cortisol, progesterone, and estradiol (Shimada & Guengerich, 1989; Flockhart, 2007). The broad 
specificity of CYP3A4 therefore prompts the use of two substrates for evaluation of enzyme activity.  
Midazolam, testosterone, felodipine, dextromethorphan, and nifedipine are commonly selected as 
marker substrates for CYP3A4 enzyme activity. Dextromethorphan, however, is also metabolised by 
CYP2D6, and as midazolam and testosterone are controlled substances, nifedipine is often selected 
as an alternative substrate (Spaggiari et al., 2014). However, nifedipine is light sensitive in solution, 
which makes it difficult to handle.  
CYP3A4 is induced by HIV antiretroviral drugs such as efavirenz and nevirapine, carbamazepine, 
glucocorticoids, phenobarbital, phenytoin, dexamethasone, rifampin, and St. John’s wort (Flockhart, 
2007). Inhibitors of CYP3A4 include ketoconazole, grapefruit juice, erythromycin, itraconazole, 
ritonavir, telithromycin, and verapamil (Flockhart, 2007). 
 
1.5 in vitro liver models for drug metabolism studies 
For studies in drug metabolism, an appropriate liver model is required, as the liver is the primary 
organ responsible for drug biotransformation. It contains many drug-metabolizing enzymes that 
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form part of phase I, phase II, and phase III biotransformation reactions. Phase I reactions consist of 
hydrolysis, oxidation, and reduction, and are mainly conducted by CYP450. Phase II reactions are 
mainly conjugation reactions executed by UGT, NAT, GST, and ST. Phase III reactions, which consist 
of efflux and excretion, are mediated by the drug transporters.  
An appropriate in vitro model should resemble the conditions expected to be found in an in vivo 
model. In addition, the selection of a model is dependent primarily on the purpose of the intended 
study. Various factors that need to be considered in the selection process include, expense, ethical 
considerations, availability, and in vivo similarity (Brandon et al., 2003). Each model has various uses, 
advantages, and disadvantages which are outlined below.  
 
1.5.1 Perfused liver 
The isolated perfused liver model gives the most accurate reflection of in vivo conditions as it 
maintains the cellular architecture of the liver and contains all cells types found in hepatic tissue. In 
addition, the presence of functional bile canaliculi allows for the collection and analysis of bile 
(Groneberg et al., 2002). There are however, several disadvantages to this model. There are no 
human livers available for perfusion and as the method of perfusion is both labour intensive and 
delicate to perform, it is difficult to reproduce. In addition, the liver is only functionally viable for a 
couple of hours after isolation (Wu et al., 1999).  
 
1.5.2 Liver slices 
The liver slice model for drug metabolism was originally introduced as a model to study organ 
function. This model offers maintains cellular architecture and the multicellular characteristics of the 
liver (Olinga & Schuppan, 2013). Liver slices contain functional drug metabolizing enzymes, however 
the expression of these enzymes are considerably lower when compared to other models such as 
human liver microsomes. Disadvantages of this model include the sourcing of liver samples, the lack 
of inter-individual variation, and maintenance of cell culture viability (Thohan and Rosen, 2002).  
 
1.5.3 Primary hepatocytes 
The primary hepatocyte model is the most similar to in vivo conditions as it reflects the diverse 
expression of drug metabolizing enzymes (Hewitt et al., 2007). Culturing isolated hepatocytes in 
monolayer results in the de-differentiation of cells. The hepatocytes lose their morphology and 
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function after a few days in culture and consequently have a limited viability (Bi et al., 2006). To 
overcome this loss of function, hepatocytes can be cultured between two layers of matrix (usually 
collagen or Matrigel) (Dunn et al., 1989). Maintaining hepatocytes in this sandwich configuration 
restores the function and morphology of hepatocytes similar to that of in vivo hepatocytes.  
1.5.4 Human liver S9 fractions 
Human liver S9 fractions are subcellular fractions obtained by the differential centrifugation of liver 
homogenates. S9 fractions contain both phase I and II enzymes and therefore provide a better 
representation of in vivo drug metabolism. S9 fractions can be used to determine whether a drug 
undergoes oxidative metabolism as they provide a simple and convenient alternative to other 
complex liver models. However, the enzyme activity in S9 fractions is substantially lower when 
compared to human liver microsomes (Brandon et al., 2003), which may result in undetected 
metabolite formation (Hakura et al., 1999). 
 
1.5.5 Human liver microsomes 
Human liver microsomes (HLM) consist of vesicles from the endoplasmic reticulum of hepatocytes. 
They can be prepared by the homogenized and differential centrifugation of liver preparations or 
obtained commercially. HLM are the most popular model for in vitro studies as they contain a vast 
variety of phase I enzymes including the various isoforms of CYP450, flavin monoxygenases, UDP 
glucuronyl transferases (UGT) (Newton et al., 2005) and are relatively affordable. HLM are employed 
in studies such as HDI and DDI, reaction phenotyping, metabolite identification, gender-based 
differences in drug metabolism, inter-individual variability in drug metabolism, and are used to 
predict in vivo clearance (Bourrie et al., 1996; Li, 2001; Venkatakrishnan et al., 2001). 
 
1.5.6 Cell lines 
Liver cell line are a less popular option for in vitro studies as the majority of available cell lines do not 
possess the phenotypic characteristics of liver tissue (Soldatow et al., 2013) – the hepatocytes are 
de-differentiated and do not completely express all drug metabolizing enzymes. The most commonly 
used cell line for drug metabolism studies is Hep G2 (Brandon et al., 2003). The more recently 
established hepatoma cell line, HepaRG, retains the phenotypic characteristics of liver tissue and has 
a stable expression of drug metabolizing enzymes (Aninat et al., 2006). However, the expression of 
these enzymes are still lower than in any other model (Marion et al., 2010) and require sensitive 
analytical methods to detect enzyme activity. 
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1.5.7 Recombinant cytochrome P450s 
The recombinant cytochrome P450 (rCYP) model consists of microsomes prepared from insect or 
bacterial cells that express a single human CYP450 isoform and NADPH reductase (Brandon et al., 
2003). rCYPs are most commonly employed in fluorometric assays using fluorogenic probe 
substrates that yield highly fluorescent metabolites in CYP-specific reactions. The probe substrates 
are composed of a blocked dye that upon metabolism is released to become highly fluorescent in 
aqueous solution (see figure 1.1). As the fluorescent metabolites are excited in the visible light 
spectrum, there is little interference from UV-excitable compounds and NADPH (Invitrogen 
Corporation, 2005). 
 
 
 
 
 
 
Commercial fluorogenic assays follow a basic protocol that most often consists of the pre-warming 
of test compounds with the enzyme, addition of NADP+ and the substrate that initiates the reaction, 
incubation, and finally the termination of the reaction. Fluorometric reading at this point is termed 
“endpoint mode,” which measures the total fluorescence produced. However, fluorescent assays 
also allow for continuous reaction monitoring, also known as “kinetic mode,” where fluorescence is 
measured at scheduled time intervals immediately after the reaction is initiated (see figure 1.2). 
An advantage of this model is that the substrate is exclusively metabolized by a single isoform, unlike 
other models that express all phase I and II enzymes (Invitrogen Corporation, 2005). This model is 
therefore useful when studying the contribution of one isoform to the biotransformation pathway of 
a particular compound (Brandon et al., 2003). As various genotypes are also available, the effects of 
polymorphisms on drug metabolism can also be studied. Recombinant enzymes are therefore used 
in the screening of new drug candidates to assess the contribution of each isoform to the 
compound’s metabolism and can be used to study HDI and DDI.  However, the expression of a single 
isoform has the disadvantage that it does not give an indication of the possible contribution of other 
metabolic enzymes. 
Figure 1.1: Schematic of the blocked non - fluorescent substrate metabolized to 
release a fluorescent metabolite (Source: Invitrogen Corporation, 2005) 
Potential sites for metabolism 
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Figure 1.2: Schematic of the fluorometric assay protocol in endpoint and kinetic mode 
(Source: Invitrogen Corporation, 2008). 
 
 
 
 
 
 
 
 
 
 
 
1.6 Selected herbal medicines 
As this study aims to add to the current knowledge of traditional African medicine, it was necessary 
to include medicinal plants indigenous to South Africa. Agathosma betulina, Siphonochilus 
aethiopicus, and Warburgia salutaris were selected for this study based on their traditional 
medicinal uses and their popularity amongst consumers.   
  
1.6.1 Agathosma betulina 
Agathosma betulina, commonly known as Buchu, is an aromatic woody 
shrub endemic to the Cederberg region in the western Cape of South 
Africa (figure 1.3) (van Wyk et al., 1997).  It has a distinct blackcurrant 
fragrance and its leaf material is commonly used for medicinal 
purposes.  Traditionally, Buchu leaves were chewed or taken orally as 
an infusion and used as a general health tonic, a diuretic, an antiseptic 
in urinary tract infections, an antispasmodic, an antipyretic, a cough 
remedy, and a treatment for colds and flu (Watt & Breyer-Brandwijk, 
1962). It can also be mixed with fat and applied to the skin to treat 
bruises, act as an antibacterial and antifungal agent, and function as an insect repellent (Watt & 
Figure 1.3: Agathosma 
betulina leaves (from 
van Wyk, 2008). 
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Breyer-Brandwijk, 1962). Today it is marketed primarily for the treatment of urinary tract infections, 
prostatitis, and as a diuretic (Flora Force, Cape Town, South Africa).  
The two major volatile compounds in Buchu extract are menthone/isomenthone (31%) (British 
Herbal Medicine Association, 1996; British Herbal Codex, 1963) and diosphenol/Ψ-diosphenol (41%) 
(Fluck et al., 1961). Other compounds include 11-17% limonene, 8% pulegone/isopulegone, and 
approximately 3% of both cis- and trans-8-mercapto-p-menthane-3-ones, which are believed to be 
responsible for the characteristic blackcurrant odour of Buchu (Kaiser et al., 1975). 
Buchu extract has possesses weak in vitro antimicrobial activity against Escherichia coli, 
Staphylococcus aureus, and Saccharomyces cerevisiae (Lis-Balchin et al., 2001), and anti-
inflammatory and antispasmodic activity has been demonstrated in vivo (Steenkamp et al., 2006; Lis-
Balchin et al., 2001).  
Buchu is sold commercially as supplements, teas, water infusions, extracts, and oils. Due to its 
flavour and fragrance, it is also used in the food industry as a flavouring agent and in the perfume 
and cosmetic industry (van Wyk et al., 1997). 
 
1.6.2 Siphonochilus aethiopicus 
Siphonochilus aethiopicus, also known as African ginger (figure 1.4), 
is one of the most popular of the traditional medicinal plants in 
South Africa. Consequently, it has been over-exploited to near 
extinction in the wild, found only in Mpumalanga and the Northern 
Province of South Africa. Currently it is preserved by cultivation. It is 
primarily indicated for the treatment of colds and flu, asthma, and 
sinusitis, sore throats, dysmenorrhea, candida, pain, hysteria and 
malaria (Watt & Breyer-Brandwijk, 1962; van Wyk et al., 1997), 
where the roots and rhizomes can be chewed, prepared by infusions, 
or steamed and the vapours inhaled (van Wyk et al., 1997).  
African ginger has shown to have in vitro antifungal and antibacterial 
effects (Coopoosamy et al., 2010), anti-inflammatory and immune-suppressing properties (Fouche et 
al., 2013), and may be used as an anti-parasitic in the treatment of sleeping sickness (Igoli et al., 
2012). It has also shown to have a cytotoxic effect, but further investigation into its possible anti-
cancer effects are required (Igoli et al., 2011). 
Figure 1.4: Siphonochilus 
aethiopicus plant with 
flowers (from van Wyk, 
2008). 
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African ginger contains a high percentage of sesquiterpenes (Igoli & Obanu, 2011). One in particular, 
siphonochilone, is responsible for the plant’s anti-inflammatory properties in the treatment of 
asthma (Gericke, 2011). Other major volatile compounds include diterpenes and furanoterpenes 
(Igoli & Obanu, 2011; Holzapfel et al., 2002).  
 
1.6.3 Warburgia salutaris  
Warburgia salutaris is the fourth most popular medicinal plant sold 
in the South African traditional health sector (Mander, 1998). Its 
English name, the pepperbark tree, is derived from the peppery taste 
of its bark that is most commonly used in traditional practices (figure 
1.5). W. salutaris is believed to be a remedy for all ailments and 
because of its popularity, is in danger of extinction in the wild.  The 
distribution of W. salutaris is now restricted to the evergreen forests 
and wooded ravines on the eastern coast of South Africa.  
W. salutaris is believed to be a panacea of all health conditions and 
some traditional healers even use the bark in almost all their 
prescribed concoctions (Mukamuri and Kozanayi, 1999). It is used in the treatment of headaches, 
colds, coughs, throat infections, chest complaints, venereal diseases, abdominal pain, rheumatism, 
malaria, sores, stomach ulcers, backache, blood disorders, skin problems, and yeast, fungal, 
microbial, and protozoal infections (Gericke, 2001). The preparation and administration of the herbal 
medicine varies for each ailment. For burns, irritations, wounds and skin complaints, the powdered 
bark is mixed with animal fat and applied topically. For respiratory infections, the bark is sometimes 
smoked, or taken orally with water.  
W. salutaris contains several drimane sesquiterpenes such as warburganal (Appleton et al., 1992), 
polygodial (Mashimbye, 1993), salutarisolide (Frum et al., 2005; Frum & Viljoen, 2006; Jaansen & de 
Groot, 1991; Kioy et al., 1990)., muzigadial (Rabe and van Staden, 2000), ugandensidial, 
isopolygodial (Mashimbye et al., 1999a), and mukaadial (Mashimbye et al., 1999b), all of which are 
responsible for its antibacterial, antifungal, cytotoxic, and molluscicidal properties (Jansen, 1993). W. 
salutaris is also said to contain mannitol (Watt & Breyer-Brandwijk, 1962), which can be used as an 
artificial sweetener.  
Traditionally, the bark is used for remedies. However, as this tree is threatened with extinction in the 
wild, more attention has recently been given to the leaf material, as it also contains approximately 
Figure 1.5: Warburgia 
salutaris leaves (from van 
Wyk, 2008). 
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the same amount of warburganal and polygodial as the bark (Drews et al., 2001) and therefore is a 
more sustainable source of W. salutaris. 
 
1.7 Justification of this study 
Recently, there has been an increase in the interest in medicinal plants and their therapeutic effect, 
specifically as a natural alternative to orthodox medication. This was marked by the increase of the 
availability of herbal products sold commercially in health care stores in South Africa (Health Product 
Association, 2008). These products are easily accessible in the form of supplements, teas, extracts, 
and essential oils, and can be obtained from any pharmacy, health store, or local market.  
Many of these natural products possess various therapeutic effects (Treurnicht, 1997; Rabie & van 
Stadan, 1997; Viljoen et al., 2006). As the majority of supplements contain natural substances, 
individuals assume the safety of these products. As discussed above, this may result in the co-
administration of supplements with prescription medication, especially in the management of side 
effects, as is often the case for chronic conditions such as HIV/AIDS and tuberculosis.  
The pharmacokinetic profiles of drugs are taken into consideration for the determination of the 
appropriate dosage regimens. However, many of these drugs are prone to pharmacokinetic 
interactions, which may lead to reduced efficacy or toxicity and the need for a change of the 
recommended dose. Many African traditional medicines contain no information on the likely risk of 
drug interactions, and the safety of these products, especially when used concomitantly with 
conventional medications, has not been established. Therefore, this study aims to determine the 
likely risk of drug interactions of three popular South African medicinal plants using fluorescence - 
based assays and recombinant cytochromes.  
 
1.8 Potential benefits of this study 
As this research provides an indication of the in vivo inhibitory potential of certain medicinal plants, 
the knowledge gained from this study can be used to plan clinical pharmacokinetic studies and 
health care practitioners can be advised on the co-administration of conventional medication and 
herbal products. The results of this and subsequent studies can be used to formulate policy 
documents regarding the safety of herbal supplements. This study therefore provides important new 
knowledge of HDI in the field of African traditional medicines. 
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1.9 Hypothesis 
The hypothesis to be tested in this study is that Siphonochilus aethiopicus, Warburgia salutaris, and 
Agathosma betulina taken as herbal supplements in addition to conventional medication, can 
interact with the metabolism of conventional drugs.  
 Medicinal plants contain biologically active molecules that may interact with CYP450 - 
mediated metabolism.  
 Common medicinal herbs have been shown to activate, induce, or inhibit CYP450 enzyme 
activity. 
 
1.10 Aim of this study 
The aim of this study is to investigate the potential inhibitory effects of herbal supplements on five 
major drug metabolizing CYP450 enzymes. 
The specific aims are to:  
• Perform in vitro inhibition studies with the three herbal supplements, namely Siphonochilus 
aethiopicus (African ginger), Warburgia salutaris, and Agathosma betulina (Buchu). 
• Interpret the observed influence of the selected herbal supplements on the metabolic 
processes in terms of concentrations required to inhibit 50% enzyme activity (IC50).  
• Determine the phytochemical composition of the volatile component of each herbal 
product. 
 
1.11 Ethical consideration 
This study was approved by the University of Stellenbosch Health Research Ethics Committee 
(Reference number X14/07/014, Appendix 1). 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
α-naphthoflavone, sulfaphenazole, ketoconazole, furafylline, erythromycin, quinidine, dimethyl 
sulfoxide (DMSO), and acetonitrile were obtained from Sigma Aldrich (St. Louis, USA). 96-well plates 
were purchased from Corning Costar Corp. (Corning, NY, USA). All reagents employed were of 
analytical grade.  
 
2.1.2 Drug metabolizing enzymes 
Vivid® CYP450 Screening kits for CYP1A2, CYP2D6, CYP2C9, CYP2C19, and CYP3A4 were purchased 
from Thermofisher Scientific (Thermofisher Scientific, MA, USA). Each kit contained P450 reaction 
buffer, P450 BACULOSOMES reagent, a fluorescent substrate, a fluorescent standard, the 
regeneration system (333 mM glucose-6-phosphate and 30 U/ml glucose-6-phosphate 
dehydrogenase in 100 mM potassium phosphate, pH 8.0), and 10 mM NADP+ in 100 mM potassium 
phosphate, pH 8.0. 
 
2.1.3 Herbal supplements 
The herbal medicines were purchased from a local pharmacy. The Buchu capsules were 
manufactured by Flora Force (Cape Town, South Africa) (batch no: FCC01390), and the Warburgia 
and African ginger tablets, sold under the names Bio-Warburgia and Bio-African ginger, respectively, 
were manufactured by Bioharmony (Durban, South Africa) (batch no: Bio-Warburgia - FT00582, Bio-
African ginger - FT000349).  
 
2.2 Methods 
The initial work of this project included in vitro assays with human liver microsomes and the analysis 
of samples with high performance liquid chromatography (HPLC).  The method development portion 
of the work proved to be challenging and we were unsuccessful in achieving adequate, consistent 
separation of metabolites in the samples.  The method of analysis was therefore changed from HPLC 
to high performance liquid chromatography tandem mass spectrometry (HPLC-MS). After each 
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assay, samples were frozen at - 80°C until the time of analysis, which could not be done on site. The 
mass spectrometry capabilities of the HPLC-MS allowed the identification and quantification of 
analytes by mass. Despite this, there was much variation between samples and duplicate samples.  
Due to time constraints, determination of the cause of variation and correction thereof was not 
possible. Consequently, the study model was changed from human liver microsomes to recombinant 
cytochromes which led to robust results on the potential of herb-drug interactions for the three 
selected plants. 
 
2.2.1 Extraction of herbal supplements for bioassays 
2.2.1.1 Tablet extraction 
10 Bio-Warburgia and Bio-African ginger tablets were powdered in a mortar and 1 g of each powder 
was dissolved in 5 ml of 60% methanol/distilled water and sonicated for three minutes. The solution 
was centrifuged at 4000 rpm (Allegra X-22, Beckman Coulter, USA) for five minutes and the 
supernatant transferred to a new tube. The pellet was again dissolved in 60% methanol/ water and 
the extraction process was repeated four times. The supernatants were all pooled in a single tube, 
filtered (0.22 μm; Whatman International LTD, Maidstone, England), and dried at 60 °C using a 
miVac concentrator (GeneVac Ltd, Suffolk, UK). The extract was reconstituted in 50% 
methanol/distilled water to a concentration of 12.5 mg/ml and stored at - 80 °C for further use.  
 
2.2.1.2 Capsule extraction 
The contents of one Buchu capsule (approximately 370 mg) was transferred to a centrifuge tube, 
weighed, and extracted with 5 ml of 60% methanol/ water, sonicated, centrifuged, and the 
supernatant transferred to a new tube according to the method described above. The extract was 
reconstituted in 50% methanol/distilled water to a concentration of 12.5 mg/ml and stored at -80 °C 
for further use. 
 
2.2.2 Gas chromatography/mass spectrometry 
Gas chromatography/mass spectrometry (GC-MS) analysis of herbal extracts was conducted to 
determine the presence of possible volatile compounds in each herbal supplement that are lost 
during an extraction process.  The analysis was conducted together with Mr L Mokwena at the 
Central Analytical Facility GC-MS Unit. 
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Three tablets and the contents of one capsule were crushed and added to separate solid phase 
microextraction (SPME) headspace vials. The samples were dissolved in 5 ml 70% methanol/distilled 
water and a 20% salt solution was added to facilitate evaporation of volatile components into the 
headspace.  The samples were vortexed for 30 seconds, sonicated for 30 minutes, and the 
headspace of the sample analysed following the method described below using a 
PDMS/DVB/Carboxen SPME fibre (grey).  
GC-MS analysis was performed on an Agilent 6890 N gas chromatograph (Agilent, Palo Alto, CA) 
coupled to a Agilent 5975 MS mass spectrometer detector. Chromatographic separation was 
achieved using a Supelco 76023AST Astec Chiraldex B-PM (30 m, 0.25 mm ID, 0.12 µm film thickness) 
column. 
The operating conditions were as follows: carrier gas, helium, with a flow rate of 1.2 ml/min; oven 
temperature program was maintained at 40 °C for 2 minutes, ramped at 5 °C/min to 80 °C, held for 2 
minutes, and finally at 20 °C/min to 180 °C and held for 5 minutes (total run time = 22 min); injector 
temperature, 200 °C; ion source temperature, 240 °C; quadrupole temperature, 150 °C;  transfer line 
temperature, 200 °C; solvent delay, 4 minutes. The mass spectral data was recorded on a mass 
selective detector (MSD) operated in full scan mode (35-600 m/z).  
The relative retention index (RRI) was calculated for all compounds. Compound identification was 
performed by comparing the mass spectral data to the Wiley 275 MS library. Quantitative data 
(percentage area) was determined from the GC peak area.   
 
2.2.3 Determination of P450 activity with Vivid® P450 assay kits 
The inhibitory effects of three herbal supplements on recombinantly expressed human P450 
enzymes were determined using Vivid® P450 screening kits (Vivid® EOMCC substrate CYP2C19 blue, 
Vivid® EOMCC substrate CYP1A2 blue, Vivid® EOMCC substrate CYP2D6 blue, Vivid® BOMCC 
substrate CYP3A4 blue, Vivid® BOMCC substrate CYP2C9 blue). The stability, robustness, 
reproducibility, and sensitivity of this model is described by Trubetskoy et al. (2005), Marks & Larson 
(2006), and Cohen et al. (2003). The assays were conducted using the manufacturers protocol 
(Invitrogen Corporation, 2005). The assays were performed in Costar opaque, black, 96-well plates 
(Corning Inc, Corning, NY, USA) in endpoint mode according to the experimental conditions listed in 
table 2.1. All assays, unless otherwise stated, were conducted in duplicate, and fluorescence was 
measured on a Cary Eclipse multi-plate reader.  
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Table 2.1: Concentration of the various CYPs in the incubate 
 CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Enzyme concentration (nM) 2 4 2 4 2 
Fluorescent substrate EOMCC BOMCC EOMCC EOMCC BOMCC 
Substrate concentration (μM) 0.3 1.0 1.0 1.0 1.0 
NADP+ (μM) 3.0 10 10 10 10 
Excitation/emission wavelength (nm) 406/460  
BOMCC = 7-benzyloxymethyloxy -3- cyanocoumarin 
EOMCC = 7-ethyloxymethyloxy -3- cyanocoumarin 
 
 
2.2.4 Inhibition assays 
2.2.4.1 Two - point screening 
The herbal products were initially screened at two concentrations.  Each well contained 40 μl of the 
herbal product (10 μg/ml and 100 μg/ml), solvent, or positive control (1.11μM and 10 μM α-
naphthoflavone for CYP1A2, 1.11μM and 10 μM sulfaphenazole for CYP2C9, 3.33 μM and 10 μM 
miconazole for CYP2C19, 1.11 μM and 10 μM quinidine for CYP2D6, and 0.05 μM and 0.5 μM 
ketoconazole for CYP3A4) diluted in reaction buffer, and 50 μl of a pre-mixture containing the 
recombinant CYP isoform and regenerating system diluted in reaction buffer. The plates were pre-
warmed for 15 minutes at 37°C before a pre-reading to determine the potential background 
fluorescence of herbal extracts, as some phytochemicals have the tendency to behave as fluorogenic 
compounds. 
Thereafter, the reaction was initiated by the addition of 10 µl of the appropriate Vivid® substrate 
and NADP+ into each well and the plate were incubated for 30 minutes at 37°C. The reaction was 
terminated by the addition of 10 µl ice-cold 20% tris(hydroxymethy)aminomethane (TRIS) base in 
acetonitrile and the enzyme activity was monitored by measuring the formation of fluorescent 
metabolites at 406nm/460nm excitation/emission spectra. The final organic solvent concentration in 
the assay wells did not exceed 1%. The amount of metabolite formed relative to a control in the 
presence and absence of an inhibitor was expressed in percentage remaining activity and calculated 
as:  
% residual activity  =
Test  -  test control
Control  -  control blank
  ×  100%  Equation 2.1 
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Analysis of the two-point screening results indicated a low signal to noise ratio for certain CYP 
isoforms. In order to avoid analytical errors and misinterpretation of data, the IC50 values for 
CYP2C9, CYP2D6, and CYP1A2 were not determined. Further assays were conducted on CYP3A4, 
CYP2C19, and CYP1A2 (TDI).  
 
2.2.4.2 IC50 determination 
Herbal products with an initial concentration of 100 µg/ml were serially diluted in a 1:3 ratio. As in 
the two-point screening, each well contained 40 μl of the herbal product, solvent, or positive 
control, and 50 μl of a pre-mixture containing the recombinant CYP isoform and regenerating system 
diluted in reaction buffer. The plates were pre-warmed for 15 minutes at 37°C before a pre-reading 
to determine the potential background fluorescence of herbal extracts.  
The reaction was initiated by the addition of 10 µl of the appropriate Vivid® substrate and NADP+ 
into each well and the plates were incubated for 30 minutes at 37 °C. The reaction was terminated 
by the addition of 10 μl 20% TRIS base in acetonitrile and the enzyme activity was monitored by 
measuring the formation of fluorescent metabolites.  
 
2.2.4.3 Time - dependent inhibition screening-normalized ratio 
Time - dependent inhibition (TDI) screening of CYP3A4 and CYP1A2 was conducted using a protocol 
adapted from Yamamoto et al. (2002) and Thelingwani et al. (2009). Enzyme activity at two 
concentrations in either the presence or absence of NADP+ was measured.   
Each well contained 40 μl of a high or low concentration of herbal product (10 µg/ml, 100 µg/ml), 
positive control (2.5 µM, 25 µM erythromycin), or negative control (2.5 µM, 25 µM ketoconazole), 
and 50 μl of a pre-mixture that contained either the recombinant CYP isoform, regenerating system, 
reaction buffer including NADP+, or a pre-mixture containing the same constituents without NADP+. 
The plates were pre-warmed for 30 minutes at 37 °C and the reaction was initiated by the addition 
of 10 μl of the appropriate Vivid® substrate and NADP+ thereafter. The plates were further incubated 
for 30 minutes at 37 °C. The reaction was terminated by the addition of 10 µl 20% TRIS base in 
acetonitrile and the enzyme activity was monitored by measuring the formation of fluorescent 
metabolites at 406nm/460nm excitation/emission spectra. The time-dependent inhibitory effect of 
each herbal product was expressed as the normalized ratio as shown in the equation below: 
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Normalized ratio=
(R +1NADP+) / (R - 1NADP+) 
(R + 1- NADP+) / (R - 1- NADP+) 
  Equation 2.2 
 
Where R + 1NADP+ is rate of the reaction in the presence of an inhibitor (herbal product, positive, or 
negative control) and NADP+, and R - 1NADP+ is the rate of the reaction without an inhibitor in the 
presence of NADP+; R + 1 - NADP+ is rate of the reaction in the presence of an inhibitor and absence of 
NADP+, and R - 1 - NADP+ is the rate of the reaction in the in the absence of both inhibitor and NADP+. 
As described by Atkinson et al. (2005), a normalized ratio value below 0.7 indicates clear TDI, a value 
between 0.7 and 0.9 indicates an intermediate TDI, and a value above 0.9 does not cause TDI. 
 
2.2.4.4 Kinetic TDI of CYP3A4  
A kinetic TDI assay was conducted on CYP3A4 to determine the change in IC50 values over time. The 
assay was conducted using a protocol adapted from Krippendorff et al. (2009). The herbal products, 
positive control, and negative control were pre-warmed at 37 °C with NADP+ and regenerating 
system for 15 minutes. The reaction was initiated by adding a pre-warmed (37 °C) enzyme and 
substrate mixture. The microplate was placed in the plate reader and fluorescence was measure at 
5-minute intervals for 30 minutes. 
 
2.2.5 Determination of IC50 
Data was exported to an Excel spreadsheet (Microsoft, USA) where the signal-to-noise ratio and 
percentage residual activity were calculated. To determine the IC50 value – the concentration of 
inhibitor required to inhibit 50% of enzyme activity – the percentage residual activity was plotted 
against the log-transformed concentrations of the herbal product or the positive control. A sigmoidal 
curve was fitted using non-linear regression and the IC50 value was calculated using GraphPad® Prism 
(GraphPad Software Inc., San Diego, CA). 
 
2.2.6 Statistical analysis 
All data were expressed as mean ± SD. An unpaired t-test was used to determine the significance of 
enzyme activity in the presence and absence of NADP+, where a p - value < 0.05 indicated statistical 
significance.  
Stellenbosch University  https://scholar.sun.ac.za
26 
 
CHAPTER THREE 
RESULTS 
 
3.1 Extraction yield of herbal products 
The calculated yields of the 60% methanolic extracts of the herbal products are shown in table 3.1. 
The table shows a high extraction yield for Buchu than the other products. This may be because the 
Buchu capsules contained approximately 370 mg of pure leaf material, while the other products 
contained 100 mg of leaf (Warburgia salutaris) or root and rhizome material (African ginger), along 
with excipients such as binders and fillers.   
 
Table 3.1: Extraction yield of herbal products 
Herbal products Yield (% W/W) 
Buchu 12.84%  
African ginger 1.55%  
Warburgia salutaris 4.47%  
 
 
3.2 GCMS analysis of herbal products 
3.2.1 Major components in African ginger 
The gas chromatogram (GC) profile of the solvent extract of African ginger is shown in figure 3.2. 33 
compounds were detected in the volatile component of African ginger and are tentatively identified 
in table 3.2. 19.47% of the compounds were monoterpene hydrocarbons and 8.28% of the 
compounds were sesquiterpenes hydrocarbons. The major compounds present in the volatile 
component of African ginger were limonene (3.28%), eucalyptol, (3.10%), and β-elemene (3.37%) 
(figure 3.1). 
 
 
 
Figure 3.1: The major compounds present in the volatile component of African ginger. 
Limonene Eucalyptol β-elemene 
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Figure 3.2: GC profile of African Ginger extract. 
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Table 3.2: Volatile components of African ginger extract 
RRI Compound Quality % Peak area % 
903 Trimethylphosphine 33 3.22 
962 α-Thujene 94 1.04 
998 α-Pinene 97 0.45 
1035 β-pinene 94 0.77 
1054 β-pinene 97 1.21 
1077 L-limonene 93 3.28 
1079 p-cymene 95 2.65 
1085 Trans-β-ocimene 95 1.07 
1094 Sabinene 94 1.13 
1105 γ-terpinene 95 0.82 
1128 Eucalyptol 99 3.10 
1133 α-terpinene 97 0.33 
1162 Allo-ocimene 98 2.18 
1184 Allo-ocimene 98 0.57 
1290 1,3,5-p-menthatriene 95 0.19 
1290 6-methylthio[1]benzothieno[2,3-c]quinoline  72 0.25 
1310 9H-pyrrolo[3',4':3,4]pyrrolo[2,1-a]phthalazine-
9,11(10H)-dione,10-ethyl-8-phenyl 
72 0.13 
1330 Terpinen-4-ol 96 0.45 
1367 Pulegone 50 0.69 
1412 (+) Cycloisosativene 92 1.20 
1424  3-(3,4-dimethoxyphenyl)-6,7-dimethoxy-1-methyl-
isochromene 
72 0.37 
1436 β-elemene 95 3.37 
1473 Trans - α- bergamotene 90 0.58 
1488 β-caryophyllene 99 0.30 
- 2-hydroxymandelic acid 59 0.21 
- α- cadinene 98 0.39 
- β-selinene 99 1.82 
- γ- cadinene 83 0.23 
- β-sesquiphellandrene 45 0.29 
- Eudesma-3,7 (11) -dien 96 0.43 
- Pyrimidine, 2-(4-nitro-3-thienyl) 59 4.71 
- Germacrene B 96 0.24 
- Epi-ligulyl oxide 80 0.64 
RRI = Relative Retention Index 
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3.2.2 Major components in Warburgia salutaris 
The GC profile of the solvent extract of Warburgia salutaris is shown in figure 3.4. 30 compounds 
were detected in the volatile component of Warburgia salutaris and are tentatively identified in 
table 3.3. 12.72% of the compounds were monoterpene hydrocarbons and 37.34% of the 
compounds were sesquiterpenes hydrocarbons. The major compounds present in the volatile 
component of Warburgia salutaris were limonene (6.66%), α-copaene (5.98%), and β-caryophylline 
(6.96%) (figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: The major compound present in the volatile component of Warburgia salutaris. 
Limonene β-caryophylline 
α-copaene 
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Table 3.3: Volatile components of Warburgia salutaris extract 
RRI Compound Quality % Peak area % 
907 Trimethylphosphine 33 1.37 
1014 3,4,4-trimethyl-1,2,6-oxadiazine N-oxide 25 2.01 
1020 Myrcene 95 3.68 
1038 Dimethylphosphorylmethane 9 8.54 
1051 L-limonene 98 6.66 
1096 Trans-β-ocimene 96 1.03 
1177 α-terpinolene 96 0.28 
1188 Thieno [2,3-b] pyridine 7-oxide 27 1.43 
1192 N-Formylnorisosalutaridine 43 0.65 
1207 α-cubebene 99 1.73 
1212 α-copaene 99 5.98 
1214 β-bourbonene 90 1.72 
1219 Camphene 91 1.06 
1226 Urocanic acid 53 0.41 
1231 Germacrene D 93 0.80 
1233 β-cubebene 91 1.80 
1242 β-caryophyllene 99 6.96 
1245 Trans-β-farnesene 96 5.00 
1257 Humulene 99 6.48 
1267 α-cadinene 96 1.90 
1269 α-cadinene 99 1.63 
1273 Neryl Acetone 11 0.44 
1297 δ-cadinene 99 2.10 
1310 l-calamanene 98 0.43 
1330 Farnesol 81 0.49 
1367 Isopropyl laurate 72 0.61 
1374 1,Z-5,E-7-Dodecatriene 60 0.92 
- Tetradecane 91 0.33 
- Trans-3,4-Dimethyl-1-cyclohexenecarboxaldehyde 58 0.49 
- 9-Isopropylenyl-biclyclonanane 49 0.39 
    
RRI = Relative Retention Index 
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Figure 3.4: GC profile of Warburgia salutaris extract. 
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3.2.3 Major components in Buchu 
The GC profile of the solvent extract of Buchu is shown in figure 3.6. 49 compounds were revealed in 
the volatile component and are tentatively identified in table 3.4. The majority of compounds 
(94.78%) were monoterpene hydrocarbons. The remaining 1.15% of compounds were 
sesquiterpenes hydrocarbons and a few alkaloids. The major compounds present in the volatile 
component of Buchu include l-limonene (45.10%), menthone (17.42%), pulegone (7.97%), and 
myrcene (7.04%) (figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The major compounds present in the volatile component of Buchu. 
L-limonene L-menthone 
Pulegone Myrcene 
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Figure 3.6: GC profile of Buchu capsule extract. 
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Table 3.4: Volatile components of Buchu extract 
RRI Compound Quality % Peak area % 
961 α-phellandrene 91 0.23 
997 α-pinene 97 0.32 
1003 α-pinene 97 1.33 
1018 Myrcene 97 7.04 
1030 Sabinene 96 0.44 
1032 Sabinene 96 0.74 
1046 β-pinene 96 0.04 
1048 β-pinene 97 0.52 
1053 3,3-Dimethyl-1-phenyltriazene  9 0.52 
1059 Camphene 72 0.05 
1063 L-limonene 98 45.10 
1081 Trans-β-ocimene 90 5.24 
1089 β-phellandrene 86 0.42 
1102 γ-terpinene 96 0.29 
1128 Eucalyptol 99 0.41 
1132 Terpinolene 97 0.15 
1154 (E)-4,8-Dimethyl-1,3,7-nonatriene 53 0.06 
1161 p-cymene 95 0.12 
1221 2-(2-Nitro-2-propenyl)cyclohexanone 59 0.07 
1237 Linalool 97 0.18 
1244 Cryogenine 27 0.13 
1261 l-menthone 99 7.23 
1278 l-menthone 98 10.19 
1324 Trans-isopulegone 96 1.06 
1356 Terpinen-4-ol 92 0.13 
1379 Trans-dihydrocarvone 97 0.19 
1349 Exo-2-Methyl-4-homobrendane 64 0.19 
1361 Pulegone 96 7.97 
1376 1-Ethyl-2-propylcyclohexane 30 0.33 
1386 Citronellene 53 0.15 
1405 Diosphenol (Buchu camphor) 89 2.53 
1419 Anabasine 40 0.29 
1434 Diosphenol (Buchu camphor) 95 1.24 
1439 Myrtanyl acetate 38 1.11 
1451 1,6-Dimethyl-3-piperidinone 53 0.17 
1476 1-(4'-pyridyl)-1-methylcyclopentane 64 0.07 
1483 8-Hydroxy-δ-4(5)-p-menthen-3-one 59 0.17 
1500 Myrtanyl acetate 90 0.58 
- 10,10-dimethyl-1,11-dehydro-bicyclo [6.3.0(1,8).0(2,6)] 
undecanone-3 64 0.09 
- (5Z)-5-ethylidene-1-methylcycloheptene;  78 0.17 
- γ-muurolene 94 0.14 
- 8-mercaptomenthone 97 0.28 
- 8-mercaptomenthone 95 0.62 
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- β-selinene 89 0.09 
- Bicyclogermacrene 98 0.24 
- Trans-γ-bisabolene 93 0.05 
- δ-cadinene 99 0.15 
- Spathulenol 81 0.07 
- (2'-nitro)-1-isopropyl-4-methyl-cyclohexanone 72 0.09 
    
RRI = Relative Retention Index 
 
 
3.3 Inhibition assays 
The potential of the selected herbal products to inhibit the enzyme activity of CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4 was investigated. Initially, reversible and irreversible inhibition was 
conducted on the specific recombinant CYP isoforms. CYP1A2, CYP2C9, and CYP2D6 resulted in a low 
signal to noise ratio (< 5.0) and were therefore excluded from IC50 determination to avoid analytical 
errors. In 1% of the total assay volume, methanol decreased CYP3A4 activity by 8%, and CYP2C19 
activity by 2%.   
 
3.3.1 Two - point screening 
Extracts of the herbal products were screened at two concentrations (10 μg/ml and 100 μg/ml) and 
the observed activity was expressed as percentages of the negative control (no inhibitor).  All herbal 
products inhibited CYP2C19 in a concentration dependent manner (figure 3.7). Warburgia salutaris 
showed the strongest inhibition, reducing CYP2C19 enzyme activity to less than 20% at high 
concentrations and less than 50% at low concentrations. CYP3A4 activity was also reduced to less than 
50% at low concentration by Warburgia salutaris and less than 30% at low concentrations by African 
ginger, indicating strong inhibition (figure 3.7).  The positive controls, ketoconazole (CYP3A4) and 
miconazole (CYP2C19), both reduced enzyme activity to less than 25%. The observed inhibition was 
not concentration dependent.  
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Figure 3.7: Two - point screening of herbal products at 10 μg/ml and 100 μg/ml. 
Miconazole (MCZ, 3.33 and 30 μM) and ketoconazole (KTZ, 0.06 and 0.05 μM) 
and were used as positive controls for CYP2C19 and CYP3A4, respectively. 
Warbur i  
 s l t ris 
rgia 
 salutaris 
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3.3.2 IC50 determination 
Warburgia salutaris, African ginger, and Buchu inhibited CYP2C19 with IC50 values of 5.88 μg/ml, 32.38 
μg/ml, and 53.52 μg/ml, respectively. Likewise, CYP3A4 was inhibited by Warburgia salutaris, African 
ginger, and Buchu with IC50 values of 5.64 μg/ml, 1.09 μg/ml, and > 100 μg/ml, respectively. The dose-
response curves from which the IC50 values were calculated are shown in figures 3.8 and 3.9.   
The IC50 values for the known inhibitors, 0.075 ± 0.036 μM (miconazole, CYP2C19) and 0.028 ± 0.011 
μM (ketoconazole, CYP3A4) were in agreement with literature - reported values (table 3.5) and 
confirm the validity of the assay.  
  
Table 3.5: Literature reported IC50 values of positive controls 
Positive control Determined IC50 values Reported IC50 values Literature reference 
Ketoconazole 
(CYP 3A4) 
0.028 ± 0.011 μM 0.018 ± 0.003 μM1 
0.1 μM 
0.083 ± 0.025 μM2 
0.22 μM 
Cohen et al., 2003 
Zambon et al., 2015 
Crespi et al., 1997 
Wu et al., 2003 
Miconazole 
(CYP2C19)  
0.075 ± 0.036 μM 0.33 μM 
0.07 μM 
0.04 μM 
0.02 – 0.5 μM 
Niwa et al., 2005 
Zambon et al., 2015 
McGinnity et al., 2005 
Peet et al., 2011 
1 Mean ± SD 
2 Mean ± SEM 
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Figure 3.8: The profile of CYP2C19 enzyme activity in the presence of African ginger, Buchu, Warburgia salutaris, and the positive control, miconazole. Data 
is expressed as Mean ± SD, n = 2. 
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Figure 3.9: The profile of CYP3A4 enzyme activity in the presence of African ginger, Buchu, Warburgia salutaris, and the positive control, miconazole. 
Data is expressed as Mean ± SD, n = 2. 
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3.4 TDI by normalized ratio 
Time - dependent inhibition was investigated for CYP1A2 and CYP3A4. By applying the normalized 
ratio, the various herbal products were categorized into clear TDI (≤0.70), intermediate TDI (0.7 - 0.9), 
and non-TDI (> 0.9) (figure 3.10A and 3.10B). African ginger showed clear TDI of CYP1A2 that was not 
concentration dependent. Warburgia salutaris showed clear TDI at 100 μg/ml and no TDI of CYP1A2 at 
10 μg/ml and Buchu showed intermediate TDI that was not concentration dependent. The negative 
control for CYP1A2, α -naphthoflavone (αNP), showed no TDI potential as it is not a TDI inhibitor. An 
established TDI inhibitor for CYP1A2, furafylline (FFL), served as the positive control and showed clear 
TDI that was not concentration dependent. 
African ginger and Warburgia salutaris both showed clear TDI of CYP3A4 at 10 μg/ml, but not at 100 
μg/ml. Buchu showed TDI of CYP3A4 that was not concentration dependent. Ketoconazole (KTZ), used 
as negative control, showed no TDI, and erythromycin (EMC), used as positive control, showed 
intermediate TDI. 
 
 
 
 
 
 
 
Figure 3.10A: The TDI classification of herbal products. Furafylline (FFL, 12.5 μM and 25 μM) 
served as a positive control. α-naphthoflavone (αNP, 12.5 μM and 25 μM) served as a 
negative control.  
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3.5 NADP+ - dependent inhibition  
To determine whether the observed inhibition was NADP+ - dependent, the enzyme activity of CYP1A2 
and CYP3A4 was determined in the presence and absence of NADP+. At 100 μg/ml, African ginger and 
the positive control, furafylline displayed NADP+ - dependent inhibition (figure 3.11A). No other 
extracts, including those at 10 μg/ml, inhibited CYP1A2 in an NADP+ - dependent manner. CYP3A4 was 
inhibited by Buchu in an NADP+ dependent manner. The inhibition observed by Warburgia salutaris 
dependent on concentration but not NADP⁺ (figure 3.11B). 
 
 
 
 
 
 
Figure 3.10B: The TDI classification of herbal products. Erythromycin (EMC, 12.5 μM and 25 
μM) served as a positive control. Ketoconazole (KTZ, 12.5 μM and 25 μM) served as a negative 
control.  
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Figure 3.11A: The inhibitory effects of herbal extracts on CYP1A2 after a 30-minute pre-
incubation in the presence or absence of NADP+. Data is expressed as Mean ± SD, n = 3. An un-
paired t-test was used to compare the percentage remaining activity for each herbal product, 
positive (furafylline, FFL), or negative control (α-naphthoflavone, αNP), where p < 0.05 was 
considered significant. 
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Figure 3.11B: The inhibitory effects of herbal extracts on CYP3A4 after a 30-minute pre-
incubation in the presence or absence of NADP+. Data is expressed as Mean ± SD, n = 3. An 
unpaired t-test was used to compare the percentage remaining activity for each herbal 
product, positive (erythromycin, EMC), or negative control (ketoconazole, KTZ) where p < 0.05 
was considered significant. 
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3.6 Kinetic time-dependent inhibition 
The inhibition of CYP3A4 by African ginger and by the positive control, erythromycin, appears to be 
time dependent, as the IC50 values of both inhibitors decreased over the 30 - minute incubation time 
(Figures 3.12A and 3.12E). The IC50 values of Buchu, Warburgia salutaris, and ketoconazole, the 
negative control, increased over time, indicating that the inhibition caused by these inhibitors is not 
time dependent (Figures 3.12B, 3.12C, and 3.12D).  Figures 3.12A, 3.12B, 3.12C, 3.12D, and 3.12E, 
show the concentration-dependency of the inhibition obtained over a 30-minute period and figures 
3.13A, 3.13B, 3.13C, 3.13D and 3.13E, show the IC50 values obtained at various incubation times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12A: The concentration-dependency of the inhibition of CYP3A4 by African ginger 
obtained at various incubation times. Data is expressed as Mean ± SD, n = 2. 
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Figure 3.11B: The concentration-dependency of the inhibition of CYP3A4 by Warburgia salutaris 
obtained at various incubation times. Data is expressed as Mean ± SD, n = 2. 
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Figure 3.11C: The concentration-dependency of the inhibition of CYP3A4 by Buchu obtained at 
various incubation times. Data is expressed as Mean ± SD, n = 2.  
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Figure 3.11D: The concentration-dependency of the inhibition of CYP3A4 by the negative control, 
ketoconazole obtained at various incubation times. Data is expressed as Mean ± SD, n = 2. 
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Figure 3.11E: The concentration-dependency of the inhibition of CYP3A4 by the positive control, 
erythromycin obtained at various incubation times. Data is expressed as Mean ± SD, n = 2  
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Figure 3.13: IC50 values obtained at various incubation times. 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSIONS 
4.1 Phytochemical constituents  
Medicinal herbs are usually prescribed as decoctions prepared by heating or boiling in water, such as 
teas or extracts, or as whole herbs, either fresh, in dried form, or as fresh juice (Watt & Breyer-
Brandwijk, 1962; van Wyk & Gericke, 2000). Some medicinal herbs are also administered in form of 
tablets or capsules containing dried herbs. Depending on the mode of administration, different 
constituents contribute to the therapeutic and other effects of the herbal product. For the present 
study an extraction method using 60% methanol/ water seemed appropriate to investigate the 
potential effects of the herbs on drug metabolism, since this method extracts both water-soluble and 
water insoluble phytochemicals. In addition, medicinal herbs contain volatile phytochemicals when 
given as whole herbs. Since these volatile components evaporate during the extraction and drying 
process, they were unlikely to have been included in the in vitro inhibition assays and are therefore 
unlikely to have caused the effects observed in this study. Therefore, the extracts used in the assays 
do not reflect the full potential activity of the investigated herbs. Volatile compounds do, however, 
possess potential inhibitory activity, and it is therefore useful to identify these components.  
Various phytochemicals contained in the methanolic extract may be responsible for the observed 
inhibition of drug metabolism. These phytochemicals can be classified as alkaloids, carotenoids, 
anthocyanins, coumarins, flavonoids, terpenes, sterols, phenols, tannins, saponins, and glycosides 
(Raaman, 2006).  
Phytochemicals are known to modulate CYP enzyme activity.  Some flavonoids are potent inhibitors of 
CYP1A1, CYP1A2, CYP1B1, CYP3A4, CYP3A6 and CYP19, while others are activators of CYP3A4 and 
CYP1A2 activity (Boek-Dohalska et al., 2001; Tsyrlov et al., 1994; Ueng et al., 1997). Various studies 
have shown that the differences in the inhibitory activity of flavonoids are due to their chemical 
functional groups. The amount of hydroxyl groups is generally related to the degree of inhibition of 
drug metabolism. The greater the amount of hydroxyl groups, the stronger the inhibitory activity. In 
contrast, flavonoids lacking hydroxyl groups stimulate enzyme activity (Boek-Dohalska et al., 2001; 
Ueng et al., 1997; Lee et al., 1994).  
There are functional groups that are responsible for mechanism-based inhibition (MBI) of CYP450s. 
This may be because metabolism of these compounds yield highly reactive oxygenated intermediates 
(Riley & Weaver, 2007). The chemical motifs implicated in MBI include alkenes (Wen et al., 2001), 
alkynes (Lin et al., 2002; Guengerich, 1990), furans (Koenigs & Trager, 1998), thiophenes (Koenigs et 
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al., 1999; Jean et al., 1996; Ha-Duong et al., 2001), alkylamines (Yamazaki & Shimada, 1998), 
dihydropyridines (Fontana et al., 2005), and benzo-1,3-dioxole (Heydari et al., 2004; Delaforge et al., 
1999).  
The tentative identification of compounds by GC-MS analysis is done by comparing individual masses, 
the full mass spectrum, and the relative retention indices of the unknown compounds to those in a 
library of known compounds. Definitive identification then relies on isolation of each compound and 
structural determination, for example by nuclear magnetic resonance (NMR). The results obtained by 
GC-MS in this study support previous studies done on Buchu, African ginger, and Warburgia salutaris 
(Fluck et al., 1961; Viljoen et al., 2006; Holzapfel et al., 2002; Igoli & Obanu, 2011; Viljoen et al., 2001; 
Mohanlall & Odhav, 2009). 
The GC-MS analysis of the respective volatile components showed that each product contained 
alkenes, as wells as other compounds that may cause inhibition of CYP450s. Warburgia salutaris and 
Buchu contain pyridines, and Warburgia salutaris and African ginger contain furans (Mohanlall & 
Odhav, 2009; Holzapfel et al., 2001). Although none of these compounds would cause the inhibitory 
effect in vitro (due to loss of the volatile component mentioned previously), they are present in some 
commercial formulations and therefore may possess an inhibitory effect in vivo.  
A detailed phytochemical analysis of the extract, such as LC-MS fingerprinting, was not performed in 
this study, and there is little published information about the phytochemical composition of the 
selected medicinal plants. In addition to the known mono- and sesquiterpenes, Buchu contains 
flavonoids, thiols (Moolla, 2005; Scott & Springfield, 2004), and phenols (Fluck, 1961), African ginger 
contains phenols, proanthocyanidin, flavonoids, and a small quantity of thiols (Nethengwe et al., 
2012), and Warburgia salutaris contains a high content of phenols and flavonoids (Steenkamp et al., 
2012). As discussed above, each of these constituents have an inhibitory potential on CYP450.  
 
4.2 Inhibition 
The initial two-point screening of the herbal products was a preliminary screening assay conducted to 
determine the potential inhibitory effects of each extract. The method serves to identify the herbal 
products that show inhibitory activity and eliminate the need for further analysis of the products that 
do no exhibit inhibitory activity. All three herbal products displayed an inhibitory effect on both 
CYP2C19 and CYP3A4 (Figures 3.8 and 3.9). Warburgia salutaris was a strong inhibitor of both 
isoforms, while African ginger displayed a more pronounced inhibitory effect on CYP3A4 than on 
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CYP2C19. As CYP3A4 metabolizes approximately 50% (Guengerich, 1999) and CYP2C19 approximately 
15% (Faber et al., 2005) of known drugs, inhibition of these enzymes may be clinically important. 
The inhibition profiles obtained from the concentration - response curves give a better indication of 
the inhibitory potential of the herbal extract. The IC50 values for the effect of Warburgia salutaris on 
CYP2C19 and CYP3A4 are 5.88 μg/ml and 5.64 μg/ml, respectively, indicating very strong inhibition. 
African ginger displayed potent inhibition of CYP3A4 with an IC50 value of 1.09 μg/ml and mild 
inhibition of CYP2C19 with an IC50 value of 32.28 μg/ml. Buchu showed weak inhibition of CYP2C19 
and very weak inhibition of CYP3A4 with IC50 values of 53.52 μg/ml and >100 μg/ml, respectively. It 
should be noted that this classification of inhibition strength is relative based on the in vitro results 
obtained; a low IC50 value indicates that a low concentration of herbal extract is needed to cause 
inhibition, whereas a high IC50 value indicates that a high concentration of herbal extract is needed to 
cause inhibition. The likelihood of inhibition observed in vivo would dependent on the amount of 
extract reaching the gastrointestinal mucosa and / or the liver which are the major sites of drug 
metabolism via CYP enzymes (Meyer, 1996).  
 
4.3. TDI normalized ratio and NADP+ dependent inhibition 
Time -, concentration -, and NADP+ - dependent inhibition of an enzyme are characteristics of 
mechanism - based inhibitors (Zhou et al., 2005).  These inhibitors are metabolized to form reactive 
metabolites that can inactivation the enzyme at which point de novo synthesis is required to restore 
enzyme activity (Halpert, 1995). As the majority of herbal products taken as supplements are used on 
a daily basis, the observed inhibition may increase over time.  The herbal products were therefore 
screened to assess the time - and NADP+ - dependent inhibitory effects on CYP3A4 and CYP1A2 using 
the normalized ratio.  
Warburgia salutaris displays NADP+ - and concentration -dependent inhibition of CYP3A4 as well as 
clear TDI at 10 μg/ml, but not at 100 μg/ml. Therefore, the inhibition of the herb increases with time 
at low concentrations, but not at high concentrations.  A possible reason for this observed inhibition 
profile is that at higher concentrations, a greater concentration of reactive metabolites is formed. 
These metabolites may result in the uncoupling of the active constituent from the binding site, 
reducing the time-dependent effect of the active constituent (Blobaum et al., 2004). At lower 
concentrations, there are less reactive metabolites that could cause this uncoupling/inhibition, which 
may explain the estimated TDI at low, but not at high concentrations.   
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African ginger caused inhibition of CYP3A4 that was time - and concentration - dependent, but not 
NADP+ - dependent. Like Warburgia salutaris, the herb displayed clear TDI of CYP3A4 at 10 μg/ml, but 
not at 100 μg/ml, which may be attributed to the greater formation reactive metabolites formed. 
These metabolites may result in the uncoupling of the active constituent from the binding site. 
Therefore, higher inhibitory concentration may have less of a time - dependent effect. 
Buchu displayed clear TDI of CYP3A4 that was both concentration - and NADP+ - dependent at both 
high and low concentrations, indicating possible MBI. Buchu displayed an intermediate TDI on CYP1A2, 
which was not concentration - or NADP+- dependent. Furthermore, Warburgia salutaris displayed time 
- and concentration - dependent inhibition of CYP1A2, and African ginger inhibited CYP1A2 in a time -, 
concentration -, and NADP+ - dependent manner, possibly indicating MBI.  
Time-dependent inhibitors have a prolonged interaction with the metabolism of drugs used in the 
treatment of chronic illnesses such as HIV/AIDS, diabetes, tuberculosis, asthma, and clotting disorders.   
Therefore, the TDI effects of each herbal product were further investigated in the kinetic time 
dependent inhibition assay.  
 
4.4 Kinetic time - dependent inhibition 
The time - and concentration - dependent inhibition of the herbal products were further explored in a 
kinetic time - dependent inhibition assay. In this assay, the effects of the herbal products are 
measured continuously rather at an endpoint after incubation, which gives a better indication of 
inhibitor activity over time. This method also distinguishes reversible and irreversible inhibitors based 
on the change in IC50 over time; irreversible inhibitors display a decrease in IC50 through the reaction 
(Naritomi et al., 2004) and reversible inhibitors display a constant IC50 (Naritomi et al., 2004) or an 
increase in IC50 through the reaction (Wu et al., 2003). 
The IC50 value of African ginger decreased throughout the reaction, indicating that it may be an 
irreversible inhibitor of CYP3A4.  The IC50 value of Buchu increased in the first 15 minutes of 
incubation, indicating reversible inhibition. For the following 10 minutes, the IC50 value decreased, 
indicating possible irreversible inhibition, and finally increased again in the last stage of the procedure.  
Although it cannot be excluded that the observed changes in IC50 values were due to variability in 
assay performance, the pattern may be explained by the formation of reactive intermediates during 
the first 15 minutes of the reaction, leading to the apparent initial decrease in IC50 value. Thereafter, 
the reactive intermediates may have uncoupled from the enzyme, recovering the relative enzyme 
activity.  
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Warburgia salutaris displayed an increase in IC50 value during the reaction, indicating that the 
observed inhibition is most likely reversible (Naritomi et al., 2004). Likewise, the IC50 value of 
ketoconazole increased during the reaction time, indicating that the inhibition is reversible. This is 
consistent with the known reversible inhibition of CYP3A4 by ketoconazole (Wu et al., 2003). 
The IC50 value of erythromycin increased and decreased throughout the 30-minute incubation period. 
However, the overall trend shows an eventual decrease in IC50 value, indicating irreversible inhibition, 
which is expected since erythromycin is known to be an irreversible inhibitor of CYP3A4.  A possible 
explanation for the variable IC50 values is the fact that the inhibition activity of erythromycin is 
sensitive to changes in temperature. Fluorescent reading could not be conducted at 37 °C and 
consequently, the microplates containing the assay incubate had to be moved been the incubator and 
the microplate reader, which may have affected the results obtained.  
The method of TDI inhibition in this study did not use different pre-incubation times as suggested by 
some authors (Burt et al., 2010). Therefore it was not possible to estimate the kinetic parameters of 
inactivation, such as KI and Kinact, the inhibition constant and the maximum rate of enzyme 
inactivation, respectively.  
 
4.5 Herb-drug interactions 
Currently, there is insufficient published information regarding the potential interactions of Warburgia 
salutaris, African ginger, and Buchu with clinically prescribed medications. As all three herbal extracts 
have shown inhibitory activity on at least two CYPs in our study, there is a high risk of HDI if used in 
combination with conventional medicines.   
Warburgia salutaris is traditionally used in the treatment of stomach ulcers, rheumatism, abdominal 
pain, backache, inflammations, malaria, protozoal infections, candida, fungal infections, microbial 
infection, and blood disorders (Van Wyk & Gericke, 2000). Consumers might use Warburgia salutaris 
as a complementary medicine for the treatment of these health concerns in conjunction with their 
standard medication such as proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), 
analgesics, macrolide antibiotics, and schizonticides. As Warburgia salutaris inhibits CYP2C19 and 
CYP3A4, drugs taken concomitantly with this herb may not be metabolized effectively, resulting in 
increased plasma concentration of those drugs. This would result in HDI that may lead to potential 
toxicity, especially with repeated usage of the herb. This inhibition may also be observed for other 
drugs that are substrates of CYP2C19 and CYP3A4. These substrates may be affected by Warburgia 
salutaris are listed in tables 4.1 and 4.2, respectively.  
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Likewise, Buchu is traditionally used for its antispasmodic, antiseptic, diuretic, antipyretic, antitussive, 
and antiseptic properties. Other uses include the treatment of coughs, colds and flu, kidney and 
urinary tract infections, haematuria, prostatitis, stomach ailments, and rheumatism (Watt & Breyer- 
Brandwijk, 1962; Van Wyk & Gericke, 2000). Conventional medicines used to treat these health 
concerns include NSAIDs, analgesics, and antibiotics. If consumers use Buchu in conjunction with their 
current medicines used in the treatment of those specified illnesses, the inhibition caused by the herb 
may result in potential drug toxicity. Buchu may also be a MBI of CYP3A4, which will inactive enzyme 
with prolonged use. De novo synthesis will then be required to resume normal enzyme activity 
(Halpert, 1995). Consumers should therefore exercise caution when using this herb. Other drugs that 
may be inhibited by Buchu are listed in tables 4.1 and 4.2. 
Traditionally, African ginger is used in the treatment of cold and flu, asthma, sinusitis, sore throats, 
dysmenorrhea, candida, pain, hysteria and malaria (Watt & Breyer- Brandwijk, 1962; Van Wyk & 
Gericke, 2000). Individuals using conventional medicine to treat those health problems may use drugs 
such as antibiotics, benzodiazepines, bronchodilators, NSAIDS, schizonticides, and analgesics. The use 
of African ginger as a complementary medicine for the treatment of these health problems may cause 
HDI, as African ginger strongly inhibits CYP2C19 and CYP3A4. In addition, African ginger showed a 
strong increase in inhibitory effect over time. Repeated administration of this herb may result in 
adverse effects. Drugs that are not used in the treatment of the specified health problems are also at 
risk for HDI. These drugs are listed in tables 4.1, 4.2, and 4.3.  
Although an IC50 profile of CYP1A2 activity was not possible in this study, the TDI assay performed 
indicated that at a concentration of 100 μg/ml, Warburgia salutaris and African ginger displayed a TDI 
effect, and Buchu displayed an intermediate TDI effect. Therefore, drugs that are substrates for 
CYP1A2 may also be affected by these herbs (table 4.3). 
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Table 4.1: Examples of CYP2C19 substrates (adapted from Flockhart, 2007) 
Drug Drug class 
Amitriptyline Tricyclic antidepressant  
Carisoprodol Muscle relaxant 
Chloramphenicol Antibiotic 
Citalopram SSRI 
Clomipramine Tricyclic antidepressant  
Cyclophosphamide Alkylating agent  
Diazepam Benzodiazepine 
Hexobarbital Hypnotic 
Imipramine Tricyclic antidepressant 
Indomethacin NSAID 
Lansoprazole Proton pump inhibitor 
Moclobemide Antidepressant (Monoamine oxidase inhibitor) 
Nelfinavir Protease inhibitor 
Nilutamide Antiandrogen 
Omeprazole Proton pump inhibitor 
Pantoprazole Proton pump inhibitor 
Phenobarbitone Antiepileptic 
Phenytoin Antiepileptic 
Primidone Anticonvulsant 
Progesterone Steroid (contraceptives) 
Proguanil Schizonticide 
Propranolol β-blocker 
Rabeprazole Proton pump inhibitor 
R-mephobarbital Barbiturate 
R-warfarin Oral anticoagulant 
S-mephenytoin Antiepileptic 
Teniposide Chemotherapeutic 
SSRI = selective serotonin reuptake inhibitor; NSAID = Non-steroidal anti-inflammatory drug 
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Table 4.2: Examples of CYP3A4 substrates (adapted from Flockhart, 2007) 
Drug Drug class 
Clarithromycin Macrolide antibiotic 
Telithromycin Macrolide antibiotic 
Quinidine Anti-arrhythmic 
Alprazolam Benzodiazepine 
Diazepam Benzodiazepine 
Nidazolam Benzodiazepine 
Triazolam Benzodiazepine 
Cyclosporin Calcineurin inhibitor 
Tacrolimus Calcineurin inhibitor 
Indinavir Protease inhibitor 
Nelfinavir Protease inhibitor 
Ritonavir Protease inhibitor 
Saquinavir Protease inhibitor 
Cisapride Gastroprokinetic 
Astemizole Antihistamine 
Chlorpheniramine Antihistamine 
Terfenadine Antihistamine 
Amlodipine Calcium channel blocker 
Diltiazem Calcium channel blocker 
Felodipine Calcium channel blocker 
Lercanidipine Calcium channel blocker 
Nifedipine Calcium channel blocker 
Nisoldipine Calcium channel blocker 
Nitrendipine Calcium channel blocker 
Verapamil Calcium channel blocker 
Atorvastatin HMG CoA Inhibitor 
Cerivastatin HMG CoA Inhibitor 
Lovastatin HMG CoA Inhibitor 
Simvastatin HMG CoA Inhibitor 
Estradiol  Steroid (oral contraceptives) 
Hydrocortisone Glucocorticoid 
Progesterone Steroid (contraceptive) 
Testosterone Steroid 
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Table 4.2 continued… 
Alfentanyl Analgesic 
Aprepitant Antiemetic 
Aripiprazole Atypical antipsychotic 
Buspirone Anxiolytic 
Caffeine Stimulant 
Cilostazol Phosphodiesterase inhibitor 
Cocaine Stimulant 
Codeine Opioid analgesic 
Dapsone Schizonticide 
Dexamethasone Glucocorticoid 
Dextromethorphan Antitussive 
Docetaxel Taxane 
Domperidone Dopamine agonist 
Eplerenone Aldosterone antagonist 
Fentanyl Opioid analgesic 
Finasteride  
Imatinib Monoclonal antibody 
Haloperidol Antipsychotic 
Irinotecan Anticancer 
levo-α-acetylmethadol Used in opioid dependence 
Lidocaine Local anaesthetic 
Methadone Opioid analgesic 
Nateglinide Oral antidiabetic 
Ondansetron 5HT3 antagonist 
Pimozide Antipsychotic 
Propranolol β-blocker 
Quetiapine Atypical antipsychotic 
Quinine Schizonticide 
Risperidone Atypical antipsychotic 
Salmeterol Bronchodilator 
Sildenafil Selective phosphodiesterase - 6 inhibitor 
Sirolimus Macrolide antibiotic 
Tamoxifen Anti-estrogen 
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Table 4.2 continued… 
Taxol Taxane 
Trazodone Antidepressant 
Vincristine Anticancer drug 
Zaleplon Hypnotic 
Ziprasidone Atypical antipsychotic 
Zolpidem Hypnotic 
HMG CoA = 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 4.3: Examples of CYP1A2 substrates (adapted from Flockhart, 2007) 
Drug Drug class 
Acetaminophen Analgesic 
Amitriptyline Tricyclic antidepressant 
Caffeine Stimulant 
Clomipramine Tricyclic antidepressant 
Clozapine Antipsychotic 
Cyclobenzaprine Tricyclic antidepressant 
Estradiol Steroid (oral contraceptives) 
Fluvoxamine SSRI 
Haloperidol Antipsychotic 
Imipramine  Tricyclic antidepressant 
Mexiletine Antiarrhythmic  
Naproxen NSAID 
Olanzapine Antipsychotic drug 
Ondansetron Selective serotonin 5-HT3 receptor antagonist 
Phenacetin Analgesic (CYP1A2 probe substrate) 
Propranolol β - blocker 
Riluzole Non-ergoline dopamine agonist 
Ropivacaine Local anaesthetic 
Tacrine Centrally acting cholinesterase inhibitor 
Theophylline Bronchodilator 
Tizanidine Muscle relaxant 
Verapamil Calcium channel blocker 
(R)warfarin Oral anticoagulant 
Zileuton 5-lipooxygenase inhibitor 
Zolmitriptan Selective agonists of 5-HT3 receptor 
SSRI = selective serotonin reuptake inhibitor; NSAID = Non-steroidal anti-inflammatory drug; 5-HT3 = 5-
hydroxytryptamine 
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4.6 Estimated concentration of extract in the gut 
The putative GIT concentration of each of the investigated herbal products was estimated using the 
percentage yield and an estimated 250 ml available GIT fluid. The calculations are based on a single 
dose of each herbal product. However their labelling recommends that two to three Buchu capsules 
should be taken twice daily (Flora Force, Cape Town), one African ginger tablet may be taken three 
times a day, and one Warburgia salutaris tablet may be taken every eight hours for ten days, or in the 
case of severe infections, two tablets every eight hours for five days (Bioharmony, Durban). It is 
therefore difficult to estimate the concentration of herbal extract in the GIT. In addition, the putative 
GIT concentrations are based on the assumption that the whole soluble extract is available for 
interaction with intestinal enzymes and transporters. The amount of phytoconstituents present in the 
GIT depends on various factors such as intestinal fluid composition, GIT transit time, and disease state 
(Fasinu, 2013). Also, not all compounds, possibly including the active phytoconstituent, are able to 
pass through the intestinal membrane. The estimates are therefore only presented as a benchmark for 
a preliminary determination of a potential in vivo effect. Further clinical studies are required to 
determine the actual in vivo effects on drug metabolism.  
 
 
Table 4.4: Calculation of estimated  concentration of the herbal extract in the gastrointestinal fluid  
Herbal products Yield (% 
W/W) 
Usual human 
dose (single; mg) 
Estimated extract 
per dose (mg) 
Putative GIT 
concentration (µg/ml) 
Buchu 12.84% 370 47.508 190.03 
African ginger 0.775%* 100 0.755 0.31 
Warburgia 
salutaris 
2.235%* 100 2.235 8.94 
Estimated extract per dose = Yield (% w/w) x single dose recommended in human. 
Putative GIT concentration = Estimated extract per dose/volume of GIT fluid (250 ml). 
* The percentage yield of African ginger and Warburgia salutaris have been adjusted (yield/2) to reflect the 
yield from a single tablet (approximately 500 mg), rather than the 1 g used for the inhibition assays. 
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Based on the above, it is not likely that African ginger will cause any clinically relevant inhibition of 
CYP3A4 after a single dose, as the estimated putative GIT concentration is lower than the 
concentration needed to cause the observed inhibition. However, this herb displays TDI and may 
cause clinically relevant inhibition with repeated administration. It is possible that inhibition of CYP450 
by Warburgia salutaris occurs under clinical conditions, as the putative GIT concentration is higher 
than the observed IC50 value. The IC50 values for CYP2C19 and CYP3A4 in the presence of Buchu were 
53.52 µg/ml and > 100 µg/ml, respectively. Although a large concentration of this herb is needed to 
cause inhibition of the two CYPs, the concentration of Buchu present in the GIT may be sufficient to 
cause clinically relevant drug interactions.  
 
4.7 Study Limitations 
The GC-MS analysis performed in this study revealed the volatile component composition of each 
herbal extract. However, this assay method does not give an indication of the phytochemical 
composition of the methanolic extract used in the in vitro inhibition studies. Other techniques, such as 
LC-MS fingerprinting and bioassay - guided fractionation would be necessary to determine the class of 
compounds present in the extract and to isolate the compounds responsible for inhibition.  
The contents of each Buchu capsule of does not correlate with the amount stated on the packaging. 
Each capsule is stated to contain 370 mg of dried leaf material, where only 360 mg, 350 mg, and 330 
mg were weighed during experimental preparation. Although the contents of the capsule are easily 
removed to determine the actual amount of plant material, this is not possible for the tablet products.   
In addition, the composition of phytochemicals extracted from these herbal products will vary 
between batches and manufacturers, depending on the location, season, and environmental 
conditions of the harvested plant. Consequently, a different batch or product may not cause the CYP 
interactions observed in this study.  
This study reports the effects of the selected herbal products on CYP2C19, CYP3A4, and to some 
extent, CYP1A2. The effects of the selected herbal products on other isoforms remain unknown. 
Further testing on other CYP isoforms and transporters should be conducted to determine whether 
the herbal products have any additional effects on metabolism and pharmacokinetics of medicines. 
 
4.8 Conclusion 
This study has shown the effects of African ginger, Warburgia salutaris, and Buchu on CYP3A4 and 
CYP2C19 and to some extent, CYP1A2. All three herbal extracts displayed an inhibitory effect on the 
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investigated CYPs. For African ginger, the inhibitory effect increased with time, which may result in a 
prolonged and pronounced inhibition with repeated usage of the product. Use of these herbs may 
therefore have clinically relevant implications. In addition, various compounds in the volatile 
component may have an inhibitory effect in vivo. Further in vivo human studies are needed to 
determine the effects of short- and long - term administration of these herbs, in order to devise 
recommendations for healthcare professionals and consumers regarding the safety of herbs when 
used concomitantly with conventional medicines. 
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